Genetherapy

Effects of chitosan nanoparticles loaded with mesenchymal stem cell conditioned media on gene expression in Vibrio cholerae and Caco-2 cells |…

June 18th, 2022

Bacterial culture and growth conditions

A multidrug-resistant clinical strain of V. cholerae stored in the collection of the Bacteriology Department of Tarbiat Modares University, Tehran, Iran, was used. The strain was resistant to tetracycline, ciprofloxacin, chloramphenicol, cotrimoxazole, and trimethoprim. The bacterial culture was performed in 1mL brain heart infusion (BHI) broth (Merck, Germany) at 37C until reaching the log phase. The bacterial suspension concentration was determined by measuring the absorbance at 540nm and comparing it with the standard 0.5 McFarland optical density (OD). According to the growth curve, the bacterial suspension with an OD of 1:0 (~108CFU/mL) was used21.

Bone marrow-derived mesenchymal stem cells (BM-MSCs) and Caco-2 cells were purchased from the Iranian Biological Resource Center and Pasteur Institute of Iran, respectively. BM-MSCs were confirmed by assaying the differentiation of the cells into osteoblasts and adipocytes using an immunohistochemistry (IHC) assay. BM-MSCs were also characterized using the flow cytometry method for CD34, CD45, CD44, and CD73 markers18.

BM-MSCs were cultured in lowglucose Dulbecco's modified Eagles medium (DMEM) (Gibco, USA) supplemented with 10% fetal bovine serum (FBS) (Gibco, USA) and 1% penicillin/streptomycin (Gibco, USA) at 37C in a humidified atmosphere containing 5% CO2. The medium was replaced after every 2days. A total of 5105 cells were seeded in a T75 flask (SPL, Korea) containing 15mL of DMEM supplemented with 10% FBS. When the confluency of the cells was near 90% at passage 2, the medium was replaced with serum-free DMEM. Subsequently, MSC CM was collected and centrifuged at 4000rpm for 30min and finally stored at 80C until use22. According to our previous study, chitosan nanoparticles were synthesized, characterized, and loaded with the supernatant of mesenchymal stem cells23. At all stages of this study, mesenchymal stem cell conditioned media (MSC CM; 1000g), chitosan nanoparticles incorporated with mesenchymal stem cell conditioned media (MSC CM-CS NPs; 1000g+0.05%), and chitosan nanoparticles (CS NPs; 0.05%) were used.

Vibrio cholerae cell suspensions were inoculated (1:100 dilution) into 1mL BHI broth medium containing 0.05% sucrose. The bacterial suspension was inoculated with MSC CM, MSC CM-CS NPs, and CS NPs overnight at 37C to evaluate the expression of biofilm genes. After this time, each well was washed three times with PBS, and adherent cells were harvested to evaluate the expression of biofilm-related genes. PBS and V. cholerae without exposure to the compounds were used as negative and positive controls, respectively. Each assay was performed in triplicate.

Caco-2 cells were cultured in DMEM supplemented with 10% FBS, 1% l glutamine (DNA Biotech, Iran), and 1% penicillin/streptomycin and incubated at 37C with 5% CO2. The culture medium was changed every two days, and when the confluency reached 80%, the cells were passaged. Since cells in monolayer culture with full confluency can form polarized cells while maintaining cell surface molecules, we explored cells at 85% confluency for all experiments24.

Caco-2 cell viability was estimated by the conventional MTT 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide assay. This was tested to evaluate the viability of Caco-2 cells after the exposure time to bacteria, MSC CM, MSC CM-CS NPs, and CS N. Briefly, 2({10}^{4}) Caco-2 cells per well were seeded into a 96-well plate and cultured for 24h at 37C. The medium was removed, and the cells were exposed to bacterial suspension (10 bacteria per epithelial cell; MOI: 10), MSC CM, MSC CM-CS NPs, and CS NPs separately for 24h. To assess cytotoxicity, a separate test was also performed for 72h. After these times, the medium was removed, and MTT solution was added for 3h at 37C. Then, the formazan crystals formed in cells were dissolved in 100L of dimethyl sulfoxide (Sigma Aldrich, USA). The resulting purple solution was measured using an ELISA reader (OD 540nm) (800 TS, BioTek, Winooski, Vermont, USA). Each assay was performed in triplicate25.

For this purpose, five groups were designed: (i) untreated Caco-2 cells (negative control); (ii) Caco-2 cells incubated with V. cholerae (MOI: 10-positive control); (iii) Caco-2 cells+V. cholerae+MSC CM; (iv) Caco-2 cells+V. cholerae+CS NPs; and (v) Caco-2 cells V. cholerae+MSC CM-CS NPs. Caco-2 cells were cultured in 96-well microplates until they reached 80% confluence. Before treatment, cells were washed three times with PBS. Then, the cells were infected with V. cholerae for 1h, and the extracellular bacteria and medium was removed and replaced with DMEM-free compounds, including 100L of MSC CM, MSC CM-CS NPs, and CS NPs, for 18h at 37C. After this time, the supernatant were removed, and then Caco-2 cells were used for total RNA extraction. Each test was performed in triplicate.

Total RNA from bacteria and Caco-2 cells was extracted using an RNA Miniprep Super Kit (Bio Basic, Canada) according to the manufacturers recommendations. The RNA was assayed by absorbance at OD260/280. Samples with a ratio of 1.82.0 were used for cDNA synthesis using Yekta Tajhiz Azma, Iran. According to the protocol, template RNA (5L), random primer (0.5L), and DEPC-treated water (7.5L) were mixed, centrifuged briefly, and incubated for 5min at 70C. Then, 5 first strand buffer (4L), dNTPs (1L), RNase 40U/L (0.5L), and M_MLV (1L) were mixed and incubated for 60min at 42C, and the reaction was terminated by heating for 5min at 70C. The cDNA samples were stored at 20C until use in the following experiment.

Conventional SYBR Green-based real-time PCR was used for target gene quantification. Real-time PCR was performed by using 10L 5 Real-time PCR Master Mix (Biomake, Houston, TX, USA), 1L of each primer (Table 1), 2L of cDNA, and 6L of distilled water in a total reaction volume of 20L in Stratagene Mx3000P real-time PCR system (Stratagene, La Jolla, CA). 16S rRNA was used as an endogenous control to normalize the expression levels of target genes of V. cholerae. Beta-actin was also utilized as an internal control to normalize the expression levels in RNA samples from Caco-2 cells. The CT of each sample was measured (CT targetCT reference). We used Caco-2 cells not treated as a calibrator, and the CT method was used to determine the difference between treated cells and the control. The fold change of gene expression level was calculated using the comparative CT (2CT).

The data were analyzed by using GraphPad Prism version 6 using one-way ANOVA and Bonferroni post hoc test. P value<0.05 was accepted as significant. The results of replications were also evaluated as the meanstandard deviation (SD).

The study was reviewed and approved by the Medical Ethics Committee of Tarbiat Modares University (Code: IR.MODARES.REC.1398.060). All methods were also carried out in accordance with the guidelines and regulations related to the committee.

See the original post here:
Effects of chitosan nanoparticles loaded with mesenchymal stem cell conditioned media on gene expression in Vibrio cholerae and Caco-2 cells |...

Recommendation and review posted by Bethany Smith

Cord Stem Cell Banking Market Gross Margins, Application, Growth,Size, Share, Trends,Top Key Players with Strategies and Forecast Designer Women -…

June 18th, 2022

Global Cord Stem Cell Banking Marketreport aids businesses in gaining knowledge about what is already there in the market, what market looks forward to, the competitive background and steps to be followed for outdoing the rivals. Effortlessness maintained in research method and application of best tools and techniques makes this market research report an outstanding. The report is bifurcated into several attributes which include manufacturers, region, type, application, market status, market share, growth rate, future trends, market drivers, opportunities, challenges, emerging trends, risks, entry barriers, sales channels, and distributors which are again detailed in the universal A business report as required to describe the topic and provide maximum information for better decision making.

The key research methodology employed here by DBMR team is data triangulation which involves data mining, analysis of the impact of data variables on the market, and primary validation. It has been assured that this business report makes available absolute knowledge and insights to the clients about the new regulatory environment which suits to their organization. The winningCord Stem Cell Banking Marketbusiness report helps clients recognize new opportunities and most important customers for their business growth and increased revenue.

With the resourceful use of technology, innovative applications, and expertise,Cord Stem Cell BankingMarket analysis report is built which successfully manages large and complex market data tables. The market report is produced based on the market type, organization size, availability on-premises, end-users organization type, and the availability in areas such as North America, South America, Europe, Asia-Pacific and Middle East & Africa. Not to mention, gathered market data and information is represented very well in the persuasive Cord Stem Cell Banking Market report with the help of graphs, charts or tables to simplify the flow for better user understanding. Market share analysis and key trend analysis are the two other major success factors of this influential market survey report.

Get a Sample PDF of the Cord Stem Cell Banking Market report https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-cord-stem-cell-banking-market

The cord stem cell banking market is expected to gain market growth in the forecast period of 2021 to 2028. Data Bridge Market Research analyses the market to grow at a CAGR of 22.2% in the above-mentioned forecast period. Increase in the number of parents storing their childs cord blood drives the cord stem cell banking market.

Cord stem cells banking is defined as the storing of the cord blood cell contained in the umbilical cord and placenta of a newborn child. This cord blood contains the stem cells which can be used in future to treat disease such as leukemia, thalassemia, autoimmune diseases, and inherited metabolic disorders, and few others.

Global Cord Stem Cell Banking MarketScenario

According to Data Bridge Market Research the market for cord stem cell banking is booming with the rising expenditure in the healthcare solutions. The increment in the novel advancement for creating good and efficient drugs to cure unmet medical challenges for the betterment of public and patients health will deliver a strategic business growth for cord stem cell banking market globally.

The rising demand of cord stem cells by pharmaceuticals enterprises has arranged an ascending array of rise in the cord stem cell banks. This significant germination will be backed by the collection placentas of new born babies after their delivery. The stem cells procured from this source are capable of regenerating advanced cells. They help in transplantation of hematopoietic stem cell, the rate of transplantation is high so thus the requirement. These inputs yields in the graphical success of cord stem cell banking market will be visible in the forthcoming period of 2019 to 2026. Few of the factors will stand in between to hinder the market growth such as high end cost of the preservation and storage of cord stem blood cells, whereas the lower rate of familiarity among the pregnant population will affect its growth.

Now the question is which are the other regions intuitive is targeting? Data Bridge Market Research has forecasted a large growth in North America due to large healthcare infrastructure and leading investment in the cord blood cells research to generate stem cells.

For more analysis on the cord stem cell banking market request for a briefing with our analystshttps://www.databridgemarketresearch.com/reports/global-cord-stem-cell-banking-market

Cord Stem Cell Banking MarketDevelopment and Acquisitions in 2019

In September 2019, a notable acquisition was witnessed between CBR and Natera. This merger will develop the new chances of growth in the cord stem blood banking by empowering the Nateras Evercord branch for storing and preserving cord blood. The advancement will focus upon research and development of the therapeutic outcomes, biogenetics experiment, and their commercialization among the global pharma and health sector.

Cord Stem Cell Banking MarketScope

Cord Stem Cell Banking Marketis segmented on the basis of countries into U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

All country based analysis of the cord stem cell banking marketis further analyzed based on maximum granularity into further segmentation. On the basis of storage type, the market is segmented into private banking, public banking. On the basis of product type, the market is bifurcated into cord blood, cord blood & cord tissue. On the basis of services type, the market is segmented into collection & transportation, processing, analysis, storage. On the basis of source, market is bifurcated into umbilical cord blood, bone marrow, peripheral blood stem, menstrual blood. On the basis of indication, the market is fragmented into cerebral palsy, thalassemia, leukemia, diabetes, autism.

Cord stem cell trading is nothing but the banking of the vinculum plasma cell enclosed in the placenta and umbilical muscle of an infant. This ligament plasma comprises the stem blocks which can be employed in the forthcoming time to tackle illnesses such as autoimmune diseases, leukemia, inherited metabolic disorders, and thalassemia and many others.

To Gain More Insights into the Market Analysis, Browse Summary of the Research Report@https://www.databridgemarketresearch.com/reports/global-cord-stem-cell-banking-market

Increased acceptance of stem cell therapeutics is the vital factor escalating the market growth, also rise in the new applications of stem cells indiseasetreatment, rise in the spending on the management of chronic diseases, rise in the growth in awareness about stem cell therapeutics and increase in the mergers and acquisitions by prominent players are the major factors among others driving the cord stem cell banking market. Moreover, rise in the technological advancements and modernization in the healthcare devices and risingresearch and developmentactivities in the healthcare sector will further create new opportunities for cord stem cell banking market in the forecasted period of 2021-2028.

However, high operating cost of stem cell therapeutics and lack of awareness in many developing economies are the major factors among others which will obstruct the market growth, and will further challenge the growth of cord stem cell banking market in the forecast period mentioned above.

The cord stem cell banking market report provides details of new recent developments, trade regulations, import export analysis, production analysis, value chain optimization, market share, impact of domestic and localised market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the cord stem cell banking market contact Data Bridge Market Research for anAnalyst Brief, our team will help you take an informed market decision to achieve market growth

Key Market Competitors Covered in the report

CBR Systems, IncCordlifeCells4Life Group LLPCryo-Cell International, Inc.Cryo-Save AGLifecellStemCyte India Therapeutics Pvt. LtdViacordSMART CELLS PLUS.Cryoviva IndiaGlobal Cord Blood CorporationNational Cord Blood ProgramVita 34, ReeLabs Pvt. Ltd.Regrow Biosciences Pvt. Ltd.Americord Registry LLC.New York Blood CenterMaze Cord BloodAABBStem Cell CryobankNew England Cryogenic Center, Inc.

Cord Stem Cell Banking MarketScope and Market Size

The cord stem cell banking market is segmented on the basis of storage type, product type, service type, source and indication. The growth amongst these segments will help you analyse meagre growth segments in the industries, and provide the users with valuable market overview and market insights to help them in making strategic decisions for identification of core market applications.

On the basis ofstorage type, the cord stem cell banking market is segmented into private banks, hybrid banks and public banks.

Based onproduct type, the cord stem cell banking market is segmented into cord blood, cord blood and cord tissue.

Based on service type, the cord stem cell banking market is segmented into collection & transportation, processing, analysis and storage.

Based on source, the cord stem cell banking market is segmented into umbilical cord blood, bone marrow, peripheral blood stem and menstrual blood

The cord stem cell banking market is also segmented on the basis of role of administration into cerebral palsy, thalassemia, leukemia, diabetes and autism.

Browse the complete table of contents at Cord Stem Cell Banking Market https://www.databridgemarketresearch.com/toc/?dbmr=global-cord-stem-cell-banking-market

Cord Stem Cell Banking MarketCountry Level Analysis

The cord stem cell banking market is analysed and market size insights and trends are provided by country, storage type, product type, service type, source and indication as referenced above.

The countries covered in the cord stem cell banking market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America dominates the cord stem cell banking market due to rise in the presence of major market participants in the US, ongoing approval of stem cell lines for disease treatment, and increasing awareness among citizens in this region. Asia-Pacific is the expected region in terms of growth in cord stem cell banking market due to rise in the older population along with as surge in prevalence of chronic diseases, and rising per capita healthcare expenditure in this region.

The country section of the cord stem cell banking market report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as consumption volumes, production sites and volumes, import export analysis, price trend analysis, cost of raw materials, down-stream and upstream value chain analysis are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.

Healthcare Infrastructure growth Installed base and New Technology Penetration

The cord stem cell banking market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipments, installed base of different kind of products for cord stem cell banking market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the cord stem cell banking market. The data is available for historic period 2010 to 2019.

Key Pointers Covered in the Cord Stem Cell Banking MarketIndustry Trends and Forecast

Market SizeMarket New Sales VolumesMarket Replacement Sales VolumesMarket Installed BaseMarket By BrandsMarket Procedure VolumesMarket Product Price AnalysisMarket Healthcare OutcomesMarket Cost of Care AnalysisMarket Regulatory Framework and ChangesMarket Prices and Reimbursement AnalysisMarket Shares in Different RegionsRecent Developments for Market CompetitorsMarket Upcoming ApplicationsMarket Innovators Study

Key Pointers CoveredMarket SizeMarket GrowthTop to Bottom Market AnalysisMarket SegmentedRecent Developments for Market CompetitorsRecent Market Value for Different CountriesMarket Value and OverView of this MarketCompany Profiling of Players of this Market

Why buy this report?

The report offers a comprehensive evaluation of the Global & Regional Market. The report includes in-depth qualitative analysis, verifiable data from authentic sources, and projections about market size. The projections are calculated using proven research methodologies.The report has been compiled through extensive primary and secondary research. The primary research is done through interviews, surveys, and observation of renowned personnel in the industry.The report includes an in-depth market analysis using Porters 5 forces model and the Ansoff Matrix. In addition, the impact of Covid-19 on the market is also featured in the report.The report also includes the regulatory scenario in the industry, which will help you make a well-informed decision. The report discusses major regulatory bodies and major rules and regulations imposed on this sector across various geographies.The report also contains the competitive analysis using Positioning Quadrants, the analysts Proprietary competitive positioning tool.

Market highlights:Assessment of the marketPremium InsightsCompetitive LandscapeCOVID Impact AnalysisHistoric Data, Estimates and ForecastCompany ProfilesGlobal and Regional Dynamics

Key Questions Answered in the Market Report

How did the COVID-19 pandemic affect the reception of by different statistical surveying and life sciences organizations? What is the viewpoint for the effective market during the conjecture time frame? What are the key patterns affecting the effect market? How might they impact the market in short-, mid-, and long-haul length? What is the end clients insight toward? What are the key variables affecting the effect market? What will be their effect in the short-, mid-, and long-haul term? What are the key open doors regions in the effect market? What is their possible in short-, mid-, and long haul length? What are the key systems taken on by organizations in the effect market? What are the key application regions of the effect market? Which application is supposed to hold the most noteworthy development potential during the gauge time frame? What is the favored sending model for the effect? What is the development capability of different arrangement models present on the lookout? Who are the key end clients of this statistical surveying quality? What is their separate offer in the effect market? Which territorial market is supposed to hold the most noteworthy development potential in the effect market during the conjecture time frame? Which are the central members in the effect market?

Report Coverage-The report involves data triangulation based on top-down and bottom-up approaches.The report contains details on revenues, growth rate, strategies, etc.The report highlights market and technological trends, new product developments, etc.The report elucidates the data gathered from interviews with reputed stakeholders such as product managers, C-level executives, among others, operating in the market.The report also highlights the impact of COVID-19 and suggests measures and strategies to grow in the approaching years.

Top DBMR Healthcare Reports:

https://www.einpresswire.com/article/574127712/internet-of-medical-things-iomt-market-share-size-growth-revenue-technologies-top-leaders-forecast-to-2028

https://www.einpresswire.com/article/574124944/clinical-trials-market-size-share-growth-segment-trends-developing-technologies-opportunities-forecast-to-2029

https://www.einpresswire.com/article/574118495/ehealth-market-by-emerging-trends-business-strategies-technologies-revenue-to-grow-at-cagr-of-23-00-by-2029

https://www.einpresswire.com/article/574106412/u-s-psychedelic-drugs-market-is-expected-to-reach-usd-9818-68-million-by-2029-by-source-drug-application-treatment

https://www.einpresswire.com/article/574288865/aesthetic-devices-market-grow-at-a-cagr-of-10-30-and-is-expected-to-reach-usd-28-865-17-million-by-2029

https://www.einpresswire.com/article/574277868/probiotics-market-size-share-trends-business-challenges-opportunities-industry-trends-key-players-and-revenue

https://www.einnews.com/pr_news/574565434/psychedelic-drugs-market-by-source-type-drugs-application-size-share-trends-growth-regional-overview-forecast

https://www.einnews.com/amp/pr_news/574553655/europe-digital-therapeutic-dtx-market-by-product-and-service-type-application-size-share-trends-and-technology

https://www.einpresswire.com/article/574545729/pharmaceutical-logistics-market-size-share-growth-segment-trends-developing-technologies-and-top-leading-company

https://www.einpresswire.com/article/574696424/hospital-staffing-market-by-staffing-service-type-trends-growth-is-expected-to-reach-usd-56-32-billion-by-2029

https://www.einpresswire.com/article/574713353/chimeric-antigen-receptor-car-t-therapy-treatment-market-by-therapeutic-application-processes-drugs-size-share

Read the original:
Cord Stem Cell Banking Market Gross Margins, Application, Growth,Size, Share, Trends,Top Key Players with Strategies and Forecast Designer Women -...

Recommendation and review posted by Bethany Smith

Jasper Therapeutics Announces Annual Virtual Stockholders Meeting to be Held on Thursday, June 23, 2022 – GuruFocus.com

June 18th, 2022

REDWOOD CITY, Calif., June 06, 2022 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. ( JSPR), a biotechnology company focused on hematopoietic cell transplant therapies, today announced that its 2022 Annual Meeting of Stockholders will be held on Thursday, June 23, 2022, at 10:00 a.m. Pacific Time. This years meeting is a virtual stockholder meeting conducted exclusively via live audio webcast on the Internet at https://www.cstproxy.com/JasperTherapeutics/2022. As described in the proxy materials previously distributed, stockholders of record at the close of business on April 26, 2022 are entitled to participate and vote at the 2022 Annual Meeting. To participate, stockholders will need to enter the 12-digit control number included in the proxy materials delivered to such stockholders.

Information about the virtual meeting webcast and instructions for how stockholders can participate in the 2022 Annual Meeting are included in the definitive proxy statement filed with the Securities and Exchange Commission on April 29, 2022 and are available on the InvestorsFinancials & Filings section of Jasper Therapeutics website at http://www.jaspertherapeutics.com or the website for the 2022 Annual Meeting at https://www.cstproxy.com/JasperTherapeutics/2022.

About Jasper Therapeutics, Inc.

Jasper Therapeutics, Inc. is a biotechnology company focused on the development of novel curative therapies based on the biology of the hematopoietic stem cell. The company is advancing two potentially groundbreaking programs. JSP191, an anti-CD117 monoclonal antibody, is in clinical development as a conditioning agent that clears hematopoietic stem cells from bone marrow in patients undergoing hematopoietic cell transplantation. It is designed to enable safer and more effective, and potentially curative, allogeneic hematopoietic cell transplants and gene therapies. A clinical study of JSP191 as a novel, disease-modifying, therapeutic for patients with lower risk MDS is also planned to begin in 2022. In parallel, Jasper Therapeutics, Inc. is advancing its preclinical mRNA hematopoietic stem cell grafts platform, which is designed to overcome key limitations of allogeneic and autologous gene-edited stem cell grafts. Both innovative programs have the potential to transform the field and expand hematopoietic stem cell therapy cures to a greater number of patients with life-threatening cancers, genetic diseases and autoimmune diseases than is possible today. For more information, please visit us at jaspertherapeutics.com.

Contacts:

John Mullaly (investors)LifeSci Advisors617-429-3548[emailprotected]

Jeet Mahal (investors)Jasper Therapeutics650-549-1403[emailprotected]

More:
Jasper Therapeutics Announces Annual Virtual Stockholders Meeting to be Held on Thursday, June 23, 2022 - GuruFocus.com

Recommendation and review posted by Bethany Smith

Global Rheumatoid Arthritis Stem Cell Therapy Market 2022 Swot Analysis by Top Key Vendors, Demand And Forecast Research to 2028 Designer Women -…

June 18th, 2022

MarketQuest.biz has announced the addition of new research titled Global Rheumatoid Arthritis Stem Cell Therapy Market from 2022 to 2028, which encompasses regional and global market data and is predicted to generate attractive valuation.The Rheumatoid Arthritis Stem Cell Therapy research covers market drivers, opportunities, limiting factors, and barriers. It provides a quantitative market study based on annual reports, product literature, industry announcements, and other sources.

The report explains the market definition, classifications, applications, engagements, and global Rheumatoid Arthritis Stem Cell Therapy industry trends are.It gives a realistic picture of the current market position incorporating original and predicted market estimates.The report gives a thorough analysis of their product portfolios to investigate the products and applications they focus on while working in the worldwide Rheumatoid Arthritis Stem Cell Therapy market. The report offers valuable suggestions to new just as set up players of the market.

DOWNLOAD FREE SAMPLE REPORT: https://www.marketquest.biz/sample-request/121261

In order to improve industrial planning, data points such as flow patterns, openings, drivers, limits, and statistics are acquired from trusted sources. The data and numbers in the research report have been provided comprehensively, using graphical and pictorial representations to understand the market better.Further when datais synthesised, statistical analysis takes place. Several processes, including screening, integration, and data extrapolation, must be performed prior to data validation.

The product types covered in the report include:

The application types covered in the report include:

The countries covered in the market report are:

The key and emerging market players in the global market include:

ACCESS FULL REPORT: https://www.marketquest.biz/report/121261/global-rheumatoid-arthritis-stem-cell-therapy-market-2022-by-company-regions-type-and-application-forecast-to-2028

Significance of The Report gives the idea about thebroad and precise understanding, industry drivers and challenges affecting the industry growth, planning the business strategies and factors leading to the market development, and evaluating the market competition and planning

Customization of the Report:

This report can be customized to meet the clients requirements. Please connect with our sales team (sales@marketquest.biz), who will ensure that you get a report that suits your needs. You can also get in touch with our executives on 1-201-465-4211 to share your research requirements.

Contact UsMark StoneHead of Business DevelopmentPhone: 1-201-465-4211Email: sales@marketquest.biz

More here:
Global Rheumatoid Arthritis Stem Cell Therapy Market 2022 Swot Analysis by Top Key Vendors, Demand And Forecast Research to 2028 Designer Women -...

Recommendation and review posted by Bethany Smith

Stem Cell Transplant the only curative treatment for Sickle cell Disease – NewsPatrolling

June 18th, 2022

World Sickle Cell Day 2022:

Bangalore, June 16, 2022: There are as many as 2.5 million carrier of the gene (Hemoglobin AS) in India that can lead to sickle cell disease, with more than 1,25,000 actual patients spread across the country, with a much higher incidence in the tribal belt of the country. Sickle cell disease is associated with a significant risk of morbidity and premature mortality, especially among children. While in the west, a child receiving comprehensive care in high-resource settings has an estimated 99% survival into adulthood. However, in India, according to an ICMR study, about 20 per cent of children with sickle disease died by the age of two, and 30 per cent children with Sickle Cell Disease die before they reach adulthood.

Dr. Biju George, Professor & Head, Department of Haematology at CMC Vellore, People with Sickle Cell Disease, may beat a risk of progressive organ damage, impaired quality of life, considerable morbidity in childhood, and risk of premature mortality in adulthood [median survival of 58 years]. Sickle Cell disease patients who are undergoing regular life-long blood transfusions, have the best chance of survival and cure with a blood stem cell transplant. This transplant can come from a sibling or a family member. However, there is only a 30% chance of finding a matched sibling donor in the same family. The remaining 70% patients look for a matching donor through a stem cell registry or donor center- a database of voluntary donors between the age group of 18 to 50 years.

Dr. Govind Eriat Nair, Consultant Hematology Hemato-Oncology and Bone Marrow Transplant Gleneagles Global BGS Hospital, Bengaluru, If there is a fully HLA matched donor in the family, there is a 90-95% chance of cure with higher cure rates in younger children of below 12 years of age. However, due to underrepresentation of Indians in the global donor data pool, patients are unable to find a match on time. Also, the awareness about the disease is less, need of the hour is to raise the social awareness about this disease. Genetic counseling and newborn screening are the way forward. Effects of endogamy, consanguinity and role prenatal counseling needs to be addressed in primary screening.

DKMS BMST Foundation India is a non-profit organization dedicated to the fight against blood cancer and other blood disorders, such as thalassemia and sickle cell disease. The organization aims to give every blood disorder patient in need a second chance at life.

To mark World Sickle Cell Day, Patrick Paul, CEO, DKMS BMST Foundation India said, Sickle cell has variance and only the severe form needs a stem cell transplant. An early transplant can help patient with severe Sickle cell disease from organ damage. With rising cases in India, it is the need of the hour that stem cell transplants are made available to more patients to save lives. But due to the misconceptions and lack of awareness about blood stem cell donation, Indians are highly underrepresented in the global donor pool. This situation can only be changed by recruiting many more potential blood stem cell donors from the Indian ethnicity.

The success of a stem cell transplant depends of donors HLA (Human Leukocyte Antigen) matching the patient. The bodys immune system has proteins known as HLA to distinguish cells that belong to the body from those that do not. DKMS-BMST helps in unrelated donor transplant process which includes enrolling and counselling the donors, get their HLA typing done, facilitate search of the donors and later facilitate the blood stem cell collection and the transplant. So, far DKMS-BMST has registered over 60,000 potential donors and have helped 60 patients with second chance at life.

Register as a potential blood stem cell donor:

Healthy individuals between 18-50 years of age can register at: dkms-bmst.org/register

All it takes is five minutes of your time and a simple 3 step process:

Step 1: Visit the site, fill up an online form and you will receive a DIY swab kit at home.

Step 2: Once you receive the swab kit, fill out the consent form and take a tissue sample from the inside of your cheeks with 3 cotton swabs provided in the kit.

Step 3: Send back your swab sample in the pre-paid envelope provided.

DKMS laboratory will then analyze your tissue type and your details will be available in the global search for blood stem cell donors. If you do come up as a suitable donor, DKMS-BMST will get in touch with you straight away. Once you come up as a match, blood stem cells will be obtained from the bloodstream using a procedure called Peripheral Blood Stem Cell Collection, which is similar to a blood donation wherein only your stem cells are taken. This is a safe, non-surgical outpatient procedure.

Read more:
Stem Cell Transplant the only curative treatment for Sickle cell Disease - NewsPatrolling

Recommendation and review posted by Bethany Smith

STEMTECH CORPORATION CHAIRMAN AND CEO CHARLES ARNOLD RECEIVES GLOBAL EAGLES BUSINESS LEADER OF THE YEAR AWARD – StreetInsider.com

June 18th, 2022

Get inside Wall Street with StreetInsider Premium. Claim your 1-week free trial here.

MIRAMAR, FL, June 16, 2022 (GLOBE NEWSWIRE) -- Stemtech Corporation (Stemtech) (OTCQB: STEK), an innovative nutraceutical company and a pioneer in the field of stem cell nutrition, announced today that Charles Arnold, Stemtechs Chairman and CEO, has received the Global Eagles Business Leader of the Year award.

The award was presented at a ceremony in Fort Lauderdale, Florida by Global Eagles International Chairman the Honorable Randy Avon. The Global Eagles is a group of diplomats, investment bankers, CEOs, University Presidents, investors and top international executives who gather regularly to network, present global projects to a group of seasoned peers, and to promote best leadership practices.

I am truly honored to receive the Global Eagles Business Leader of the Year award, said Chuck Arnold, Chairman and CEO of Stemtech. The Global Eagles community is a distinguished group that includes top leaders in business, the investment community, government and academia. The impact that this organization and its members have had on international development and infrastructure is hard to overstate. I continue to enjoy the camaraderie and friendship of fellow Global Eagles members, and I look forward to being a member for many years to come.

About Stemtech Corporation

Stemtech Corporation, a leading nutraceutical company with a direct sales distribution model, was founded on April 18, 2018, after acquiring the operations from its predecessor Stemtech International, Inc. which was founded in 2005. From 2010 through 2015, Stemtech International, Inc., was recognized four separate times on the Inc. 5000 Fastest-Growing Companies list. In 2018, the Company underwent an extensive executive reorganization, and continued operations under new leadership. Stemtech specializes in creating products and formulas that are patent-protected in the U.S. and in select international markets. The Companys patented formulas help the release, circulation and migration of the bodys adult stem cells from its bone marrow. The Company markets its products under the following brands: RCM System, stemrelease3, Stemflo MigraStem, OraStem (Oral Health Care), and D-Fuze (EMF Blocker). Its products are all-natural and plant-based and manufactured under cGMP (Current Good Manufacturing Practices) under the auspices of the Dietary Supplement Health and Education Act (DSHEA). For more information, please visit http://www.stemtech.com.

Forward-Looking Statements

This announcement contains forward-looking statements within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Such statements include but are not limited to statements identified by words such as "believes," "expects," "anticipates," "estimates," "intends," "plans," "targets," "projects" and similar expressions. The statements in this release are based upon the current beliefs and expectations of our company's management and are subject to significant risks and uncertainties. Actual results may differ from those set forth in the forward-looking statements. Numerous factors could cause or contribute to such differences, including, but not limited to, results of clinical trials and/or other studies, the challenges inherent in new product development initiatives, the effect of any competitive products, our ability to license and protect our intellectual property, our ability to raise additional capital in the future that is necessary to maintain our business, changes in government policy and/or regulation, potential litigation by or against us, any governmental review of our products or practices, as well as other risks discussed from time to time in our filings with the Securities and Exchange Commission, including, without limitation, our latest 10-Q Report filed onMay 16th, 2022. We undertake no duty to update any forward-looking statement or any information contained in this press release or in other public disclosures at any time. Finally, the investing public is reminded that the only announcements or information about Stemtech Corporation which are condoned by the Company must emanate from the Company itself and bear our name as its Source.

For Further Information, Contact:

Investor Relations: Frank J. Pena, 908-675-0581,

[emailprotected]

Read the original here:
STEMTECH CORPORATION CHAIRMAN AND CEO CHARLES ARNOLD RECEIVES GLOBAL EAGLES BUSINESS LEADER OF THE YEAR AWARD - StreetInsider.com

Recommendation and review posted by Bethany Smith

BioRestorative Therapies Announces Clinical Site Initiation for the Company’s Phase 2 Clinical Trial to Treat Chronic Lumbar Disc Disease (cLDD) -…

June 18th, 2022

First Site Will Enroll First Patient in the Clinical Study

MELVILLE, NY., June 13, 2022 (GLOBE NEWSWIRE) BioRestorative Therapies, Inc. (the Company or BioRestorative) (NASDAQ: BRTX),a clinical stage company focused on stem cell-based therapies, today announced site initiation for its Phase 2 clinical trial targeting chronic lumbar disc disease (cLDD). The Denver Spine and Pain Institute is the first clinical site to be initiated. Additional selected sites are expected to be initiated in 2022.

BioRestoratives Phase 2 trial is a double-blind controlled, randomized study to evaluate the safety and preliminary efficacy of a single dose intradiscal injection of the Companys autologous investigational stem cell-based therapeutic, BRTX-100. A total of up to 99 eligible patients will be randomized at up to 15 centers in the United States to receive either the investigational drug (BRTX-100) or control in a 2:1 fashion.

Currently there are no approved, cell-based therapies for cLDD. While there is encouraging data that suggests that patients with cLDD could benefit from autologous stem cell transplants, the low oxygen micro-environment of the disc makes cell-based therapies challenging. BRTX-100 is manufactured under low oxygen conditions and engineered to survive this environment, said Scott Bainbridge, M.D., Principal Investigator for the BRTX-100 trial at The Denver Spine and Pain Institute. Positive proof-of-concept data in this trial could be disruptive and support the potential applicability of BRTX-100 to other spine and musculoskeletal disorders where low oxygen micro-environments are found.

We are pleased to initiate the first of several sites across the United States that will be enrolling for the trial, said Lance Alstodt, Chief Executive Officer of BioRestorative Therapies. Our sites have been carefully reviewed and selected and have clinical expertise in treating patients who could potentially benefit from BRTX-100. We look forward to working with the principal investigators and their clinical trial teams.

About BioRestorative Therapies, Inc.

BioRestorative Therapies, Inc. (www.biorestorative.com) develops therapeutic products using cell and tissue protocols, primarily involving adult stem cells. Our two core programs, as described below, relate to the treatment of disc/spine disease and metabolic disorders:

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events or results to differ materially from those projected in the forward-looking statements as a result of various factors and other risks, including, without limitation, those set forth in the Companys latest Form 10-K filed with the Securities and Exchange Commission and other public filings. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and the Company undertakes no obligation to update such statements.

CONTACT:Email:ir@biorestorative.com

Read more:
BioRestorative Therapies Announces Clinical Site Initiation for the Company's Phase 2 Clinical Trial to Treat Chronic Lumbar Disc Disease (cLDD) -...

Recommendation and review posted by Bethany Smith

Surgery gives teen opportunity to help other kids with cancer – Houston Chronicle

June 18th, 2022

For every procedure Hallie Barnard has undergone at MD Anderson, she receives a bead. The yellow ones symbolize each night in the hospital. The ones that glow in the dark represent radiology appointments.

Theyre for every poke, every wound cleaning, every physical therapy appointment, the 13-year-old said.

MD Anderson launched its Beads of Courage program in 2008 so young patients could document their journeys through cancer treatment. Collecting colorful strings of beads also provides some incentive to show up at dreaded doctor appointments.

Hallie has more than 350 feet of beads.

They symbolize everything that Ive gone through in the past four years, the Denton resident said.

Still, Hallie is less concerned about her own struggles through osteosarcoma, a cancer that begins in the bones, than she is with shining a light on the challenges other children face.

Every time I show people my beads, it dawns on them that children are going through so much, she said. And there are children with longer beads than I have.

According to the American Childhood Cancer Organization, about 15,780 children are diagnosed with cancer in the U.S. each year.

Their studies indicate 1 in 285 children will be diagnosed with cancer before their 20th birthday and that cancer is the leading cause of death for children between the ages of 4 and 14 in the country.

Children are dying of cancer at astonishing rates, Hallie said.

Regardless, she said, childhood cancer research is underfunded. Less than 4 percent of the federal budget for cancer research is dedicated to its study, according to the Childrens Cancer Research Fund, a national nonprofit.

I dont want any of my friends to die anymore, Hallie said. I want to show them that I am there for them. I am their voice. I can speak for those who cannot speak for themselves.

Hallies Heroes, the nonprofit she started with her parents, Elyse and Jesse Barnard, helps fund childrens cancer research.

But thats not how it began. The organization was founded to inspire individuals to register as bone marrow donors. Because, at the time, Hallie was facing another seemingly insurmountable challenge finding a match for herself.

Hallie was diagnosed with Diamond-Blackfan anemia when she was 13 months old.

Your bone marrow is basically what makes your red blood cells, she said. And with DBA, that fails to happen, Hallie said.

Elyse said her daughter did not seem to be growing normally or hitting milestones at the right time during her first year of life.

Our pediatrician would tell me everything was OK, she said. As a first-time mom, we tend to worry about everything, but I knew that something was wrong.

That fear was validated when Hallie went for her 12-month checkup. A blood test revealed low levels of hemoglobin, and she was admitted to the hospital.

Diagnostics pointed to Diamond-Blackfan anemia but doctors were still skeptical due to the rarity of the disease, Elyse said.

In the end, Hallie had a diagnosis. But treatment options were even more elusive.

Only five to seven babies per million have Diamond-Blackfan anemia, according to St. Judes Research Hospital.

Blood transfusions and steroids can be used to manage symptoms, but both take a toll on the body, Elyse said.

Stem cell transplants offer the only possible cure. The issue is finding a donor.

Theres just a 1 percent chance of finding a match for bone marrow transplants, Hallie said.

Her family began looking and moved from Virginia to Texas, after learning that Dallas had one of the four hospitals in the U.S. specializing in the disorder.

Out of the Barnards search for donors, Hallies Heroes was born.

In the search for her own bone marrow donor, other matches were made. So far, there have been 184 and the organization has inspired more than 8,000 people to join the bone marrow registry.

To its mission, Hallies Heroes added funding for Diamond-Blackfan anemia research and covering medical bills.

Hallie found her own match for a bone marrow transplant when she was 9. The procedure was scheduled the following year, 2018.

She was in the hospital for 60 days, kept in isolation for the duration to protect her fragile immune system, which was wiped out by chemo.

After 100 days, the bone marrow transplant is usually considered fully integrated, Elyse said.

You basically do a happy dance, because you have a new immune system, she said. We thought we were in the clear.

But at 120 days, Hallie had a new symptom.

I started getting horrible pains in my leg, she said. We found a small bump, the size of a mosquito bite.

The growth was right above her left knee. Doctors told her to draw a circle around it to see if it grew.

In a week, it had doubled, Hallie said.

Diagnostics revealed the bump was indeed a tumor.

In March 2019, Hallie was diagnosed with osteosarcoma, a bone cancer that develops most often in children and young adults.

Hallie was presented with a few different choices. She could opt for an amputation or limb salvage surgery to remove diseased bone and replace it with a metal implant or a bone graft, called at allograft, from another person.

We wanted to get a second opinion, Hallie said. Our doctor said, I studied under this amazing woman, Dr. Lewis. Yall should go to MD Anderson.

Dr. Valerae O. Lewis serves as the inaugural chair of orthopedic oncology at the hospital. In fact, she created the Department of Orthopedic Oncology in 2014.

The Barnards made an appointment to see her in mid-April 2019.

Data from MD Anderson shows that between 800 and 900 cases of osteosarcoma are diagnosed annually in the U.S. About half of these are children and teens.

Lewis presented Hallie with three options. You can do an amputation, she began.

Historically, that was the only choice available to remove the tumor completely. But now there are additional options limb-salvaging surgery and rotationplasty, Lewis said.

Limb-salvaging surgery can be performed if the cancer has not metastasized.

Limb-salvage is a great option, because it gives kids the ability to keep their legs, Lewis said. But it does take a toll.

Patients activity levels are restricted and additional operations are needed down the road, probably every 15 to 20 years.

The third option, a rotationplasty, removes the tumor along with the middle part of the leg and the knee. The surgeon then rotates the lower leg 180 degrees before reattaching it to the thigh.

Its like an amputation, but we create a new knee, Lewis said.

Rotationplasty allows patients to be higher functioning. Its easier to walk, Lewis said. You can bike, skate and swim. Everything you need a knee for, you can do.

Hallie chose rotationplasty. Surgery was scheduled for late June 2019, and she had chemo before and after surgery.

She was 11 at the time and had complications while healing, including infections. She needed a wound vacuum for about 11 months. When Hallie finished chemo in 2020 in Fort Worth, her bones had not yet fused.

Then, Dr. Lewis came up with a genius idea, Hallie said.

Lewis inserted a titanium rod into the nonhealing site to help.

Hallie said that Lewis restored her confidence.

Theres a point when a patient gives up. And theres also a point when a doctor gives up. She said that she had not given up on my leg yet, Hallie recalled.

After rotationplasty, a prosthesis is worn, and patients have to relearn how to walk.

Even though the ankle now functions as the knee, it is entirely different from the typical configuration, Lewis said.

The foot fits into the prosthesis, she said. And one needs to remember that it is a functional foot interfacing with the prosthesis.

The toes can provide balance and aid in powering the prosthesis, Lewis added. The plantar surface also allows for bearing weight.

Hallie was at MD Anderson for about seven months, working on both physical and occupational therapy, until she headed back to Denton April 8.

Hallie has progressed nicely and is walking distances without support, Lewis said.

With further physical therapy and continued dedication she anticipates Hallie will be running, skipping and jumping in the future.

Hallies follow-up appointments at MD Anderson are scheduled every three months.

When Hallie was first diagnosed with osteosarcoma, she remembers telling her mother, God put me back in the hospital to help other children.

Now she advocates for both children with cancer and those with Diamond-Blackfan anemia.

At one point, while Hallie was healing from surgery, Elyse and Jesse went to a wall where donors names are displayed on the ninth floor of MD Anderson.

Every day, her dad and I passed the wall, Elsye said. One day, she wanted to see Hallie added to the names.

After changing the bylaws of the nonprofit, Hallies Heroes pledged $50,000 over five years in support of Lewis research in the area of pediatric sarcoma.

Hallie went on the wall in November.

It was really cool to come full circle with that, Elyse said. We were once there as parents, not knowing if our child would survive and seeing all the people donate money so that she could.

Now were giving back, because we want other children to survive, she added.

The funding will make a significant impact, Lewis said, and will go toward researching treatments for pediatric sarcoma.

Hallie is a success story, Lewis said. She is our ambassador and is a cheerleader to other patients. She wants to give back and help other kids like her.

Peyton is a Houston-based freelance writer.

Read the original post:
Surgery gives teen opportunity to help other kids with cancer - Houston Chronicle

Recommendation and review posted by Bethany Smith

Anadrole Reviews – Best Alternative to Anadrol Steroid? Any Side Effects? – MarylandReporter.com – MarylandReporter.com

June 18th, 2022

Anadrole Reviews Does CrazyBulks Anadrole (Anadrol) Supplement Really Work? Do the ingredients have any negative side effects? Read its price, results, dosage & customer reviews!

Official Website: Click Here

What is Anadrole?

Anadrole is a muscle-building supplement developed by CrazyBulk that imitates the effects of the anabolic steroid Anadrol and androgen oxymetholone, which treat low levels of red blood cells.

Its primary function is to stimulate the synthesis of red blood cells in your body, which in turn helps to reduce the symptoms of anemia, including lethargy, muscle weakness, and weariness, among other symptoms.

Anadrole from CrazyBulk contains high concentrations of various proteins, amino acids, and ergogenic herbs.

These ingredients all work together to produce the same results as oxymetholone without harming your health.

It is designed to offer all of the advantages that its equivalent, available only by prescription, does, but without any potentially harmful effects.

Because the steroid Anadrol increases your stamina and assists you in fighting exhaustion, the Anadrole supplement makes it possible for you to attain bigger improvements in muscle mass.

It can effectively assist in growing muscle and bolstering muscle strength, and it speeds up the healing of muscles after exercise.

Your workouts will be more effective if you include them in your routine, and it is simple to use Anadrole in any fitness program.

Improve your physical performance, maintain your muscle mass, and shed excess weight with the help of this cutting-edge muscle-building supplement Anadrole.

It provides sustained energy surges, enabling you to work better and for longer at the gym. As a result, you can break through muscle-building plateaus more easily.

You will be able to achieve your fitness objectives more quickly and easily if you consistently apply this powerful method.

Click to Learn More About the Anadrole on the Official Website

How does Anadrole supplement work?

It accomplishes this by utilizing two metabolic processes stimulated by its proprietary formulas. To begin, taking this Anadrole can enhance a process known as erythropoiesis, which takes place in the bone marrow.

To put it another way, the stimulatory impact that the capsules have on the bone marrow stem cells causes an increase in the creation of red blood cells.

Because of this increased RBC, more oxygen will be carried into organs, particularly the muscles.

As a consequence, the muscles may be able to recover from weariness more quickly.

The second impact is known as the androgenic effect, which plays a role in both the manufacture of testosterone and the improvement of the bioavailability of male hormones.

Testosterone plays a significant role in the initiation of fat burning, which is beneficial to the process of creating lean muscle.

Click to Learn More About the Anadrole Supplement

Benefits of consuming Anadrole Capsules:

The Anadrole supplement sold by CrazyBulk is comprised of a potent composition that helps maintain your muscle health in a variety of ways.

Shocking New Anadrole Report: This May Change Your Mind

What are the Ingredients used in Anadrole Supplement?

Anadrole has appropriate quantities of natural substances that improve muscle strength, growth, and recovery and is packed full of these nutrients.

They cooperate to alleviate the symptoms associated with iron deficiency and low numbers of red blood cells.

In light of scientific research, the following is everything you need to know about the components that are found in Anadrole and the benefits that come from them:

Tribulus Terrestris, a plant native to the Mediterranean region that bears fruit and is a member of the caltrop family, is traditionally employed in herbal medicine as an aphrodisiac.

It is loaded with compounds that improve sexual performance in both men and women and has these substances in plenty.

The compounds found in the fruit of the Tribulus Terrestris plant have the power to interfere with the function of particular hormones in your body beneficially, which results in the production of ergogenic effects.

Anadrole from CrazyBulk has a total of 500 mg of Tribulus Terrestris fruit extract packed into every serving.

Soy protein is a type of protein that can be acquired from soybeans. It is unique in that it contains all of the essential amino acids your body cannot produce independently.

Because it is a complete protein, it stimulates muscle protein synthesis in your body by supplying your body with significant quantities of all of the required amino acids.

Losing weight, maintaining good cholesterol levels, and gaining muscle are all benefits. The Anadrole sold by CrazyBulk includes 200 mg of soy protein extract in every serving.

Whey protein, the primary protein found in dairy products, encourages the development of new proteins within your body by providing it with all of the needed amino acids.

It is a protein that is broken down very quickly and is an essential component in the process of creating new muscle protein.

Anadrole sold by CrazyBulk comes with 200 milligrams of whey protein concentrate in every single serving.

Nitric oxide can be produced from the amino acid L-arginine when it is metabolized in the body.

L-arginine has a role in maintaining healthy blood flow by contributing to the production of nitric oxide, which is important for keeping your blood vessels relaxed.

In addition, it influences particular hormones in your body, such as insulin and growth hormone, amongst others.

L-carnitine is a naturally occurring amino acid derivative that aids in synthesizing energy and enhances thermogenesis and encourages body fat reduction.

Your endurance will improve due to acetyl-l-role carnitine in the mitochondria, and you will be able to push yourself further during your workouts.

Acetyl l-carnitine is the primary factor responsible for Anadroles capacity to increase ones energy levels. Anadrole sold by CrazyBulk contains 50 mg of acetyl l-carnitine in every serving.

Shocking Results of This Anadrole Supplement Reported!

Pros of Anadrole:

Cons of Anadrole:

Check Out Anadrole Supplement Reviews From Real-Life Customers

Side effects of Anadrole Crazy Bulk

Anadrole does not contain an API, which stands for active pharmaceutical ingredient, or, to put it another way, the chemical compound responsible for carrying out all of the necessary functions.

The so-called beneficial effects are caused by certain herbs and the extracts of those herbs, similar to the way that Ayurvedic medications and other traditional treatments function.

Because you are genuinely consuming certain plant components in capsule form, there are no adverse consequences, unlike those caused by steroids, such as kidney failure, liver damage, high blood pressure, or organ damage.

Click to Order Anadrole Steroids From the Official Website (60 Days Money-Back Guarantee)

Pricing of Anadrole and Return Policy

One bottle of CrazyBulks Anadrole costs $64.99 and includes 60 individual capsules in each bottle.

If you buy two bottles at once, you will receive a free bottle as a bonus, and the total cost of 3 bottles is $129.98.

When you place an order straight through the official CrazyBulks Anadrole supplement website, you get free shipping on all of your purchases, no matter where you are.

Check Current Anadrole Supplement Pricing & Discounts!!

How to use Anadrole?

To experience the maximum potential of Anadrole, the manufacturer suggests taking two capsules each day for at least two months.

Because it requires the body a little bit more time to digest it, it is recommended that the Anadrole be taken first thing in the morning.

It is recommended that you take both capsules at the same time, at least twenty minutes before breakfast, to ensure that the Anadrole capsules are adequately absorbed along with the food.

When taking capsules, it is advisable to consume them with water or fruit juice; alcohol of any kind should be avoided at all costs.

The body is better able to properly distribute the tablets contents when it is given for 60 days consecutively followed by 10 days off cycle.

Click to Get the Best Deal on Anadrole from the Official Website

Anadrole Reviews Final Verdict

Anadrole is a great option for beginners and intermediates looking for a supplement that will help them gain muscle, increase their endurance and stamina, and improve their lean body mass.

This one, in contrast to other legal steroids, has a price tag that is slightly more reasonable, and its impact is comparable to that of the original steroid.

This products capacity to increase RBC counts assists in the fight against fatigue and shortens the time needed for recovery after exercise.

As a result of the herbal formulation, Crazy Bulk products do not cause any unfavorable health effects and do not cause any side effects.

Get Anadrole Now With Special Discount (Worldwide)!

Disclaimer: We are a professional product review website. We might receive compensation when you buy through our website, we may earn a small affiliate commission. The information contained on this website is provided for informational purposes only and is not meant to substitute for the advice provided by your doctor or other healthcare professional. The products have not been evaluated by the Food and Drug Administration and are not intended to diagnose, treat, cure, or prevent any disease.

People also search for: anadrole reviews anadrole review anadrole crazy bulk review anadrole side effects anadrole crazy bulk anadrole vs anadrol anadrole crazy bulk side effects anadrole results anadrole ingredients

Continued here:
Anadrole Reviews - Best Alternative to Anadrol Steroid? Any Side Effects? - MarylandReporter.com - MarylandReporter.com

Recommendation and review posted by Bethany Smith

New Amrita Hospital is all set to open in Faridabad in August this year; 2,400-bed facility will become Indias biggest private hospital – The…

June 18th, 2022

Amrita Hospitals announced on Thursday that its new 2,400-bed campus will soon be open to the public in Faridabad in August this year. During the press conference on Thursday, hospital management announced that the new Amrita Hospital is spread across 133 acres of land in Faridabad and it will be the biggest private sector hospital in India.

This would be the second large-scale Amrita Hospital in India after the iconic 1,200-bed Amrita Hospital in Kochi, Kerala, which was established 25 years ago by the Mata Amritanandamayi Math.

The new hospital is located at Sector 88, Faridabad and it will have a total built-up area of 1 crore sq. ft., including a 14-floor-high tower that will encompass the key medical facilities and patient areas. During the press conference, Swami Nijamritananda Puri, Head, Mata Amritanandamayi Math, Delhi announced that the 81 specialties at the hospital will include eight centers of excellence, such as oncology, cardiac sciences, neurosciences, gastro-sciences, renal sciences, bone diseases and trauma, transplants, and mother and child.

The hospital will become operational in stages, with 500 beds opening in August this year. In two years, this number will rise to 750 beds, and further to 1,000 beds in five years. When fully operational, the hospital will have a staff of 10,000 people, including over 800 doctors.

On how the new hospital has incorporated the aspects of pandemic-induced demands, Dr. Sanjeev K Singh, Medical Director, Amrita Hospital, Faridabad told Financial Express.com: We have learned a lot from the pandemic. The construction of the hospital began 5-6 years ago and the learnings from the pandemic also got incorporated along the way. For example, any patient who comes in an emergency gets facilitated in a 40-bed setup. In that set-up, we have a decontaminated area in which anyone who needs to shower will be sent there. We have four negative pressure rooms and if we have any suspected cases of covid or covid-like diseases we can send them to concerned specialists. The mechanism of shifting is also planned and implemented. In all critical care units, there are positive pressure isolation rooms.

The massive facility will also include 534 critical care beds which is the highest in India, the hospital management claims. The hospital campus will also include 64 modular operation theaters, most advanced imaging services, fully automated robotic laboratory, high-precision radiation oncology, most updated nuclear medicine, and state-of-the-art 9 cardiac and interventional cath lab for clinical services. Cutting-edge medical research will be a strong thrust area, with a dedicated research block spread across a 7-floor building totaling 3 lakh sq. ft with exclusive Grade A to D GMP lab with focus on identifying newer diagnostic markers, AI, ML, Bioinformatics etc.

Dr. Singh also told Financial Express.com that they want to integrate all aspects of medical science and bridge the gap between clinicians and scientists.

In Kochi, we have established tissue engineering, a nano-medicine-based cardiac stent, bone growth, and lots more. What we are looking at Faridabad campus is developing something new in stem-cell therapies. We want to create techniques like creating human cells on our own in our GMP labs as generally, we rely on international counterparts for such procedures. Recently, we conducted research in which we found that we can use patient pluripetin stem cells in tumours and it will destroy them. For us, oncology is the big thrust area but other areas will be a focus too. The intent of our research facility will be to make the high-end expensive equipment and treatments cost-effective for the common man. We want to integrate medicine, engineering, biotechnology, and other segments altogether, Dr. Singh told Financial Express.com.

Dr. Singh also said that they have already been awarded the Advanced ICMR Clinical Trial Unit and this will enable them to conduct their trials in the new facility.

Mata Amritanandamayi has allocated a certain amount of seed money to initiate research. On the basis of submitted proposals, things will materialise and start, he added.

Dr. Singh also told Financial Express.com that the new hospital will also be empaneled. There is a process of 3-6 months and then after medical facilities will be available under all panels like ECHS, CGHS and other TPAs, he added.

During the press conference, Dr Singh also informed that the hospital will be among the very few facilities in the country to conduct hand transplants, a specialty pioneered by Amrita Hospital in Kochi. We will also do transplants of liver, kidney, trachea, vocal cords, intestine, heart, lung, pancreas, skin, bone, face and bone marrow, he said.

Training of medical students and doctors will be a strong focus area. The hospital will have state-of-the-art robotics, haptic, surgical-medical simulation centre spread across 4 floors and 1.5 lakh sq. ft area, the biggest such learning & development facility for doctors in the country. The facility will also host a medical college and the countrys biggest allied health sciences campus, he stated.

Moreover, the management also informed that ultra-modern Amrita Hospital at Faridabad would be one of Indias largest green-building healthcare projects with a low carbon footprint. It is an end-to-end paperless facility, with zero waste discharge.

There is also a helipad on the campus for swift transport of patients and a 498-room guest house where attendants accompanying the patients can stay, they said.

Read the original post:
New Amrita Hospital is all set to open in Faridabad in August this year; 2,400-bed facility will become Indias biggest private hospital - The...

Recommendation and review posted by Bethany Smith

Take These 7 Vitamins if You Want Longer, Thicker Hair – CNET

June 18th, 2022

According to the American Academy of Dermatology Association, it's normal to shed between 50 to 100 hairs daily. However, if you're experiencing more hair loss on a regularly, other factors could be the cause. Hair loss can result of genetics, medical conditions, stress and vitamin deficiencies.

Diet plays a crucial role in developing healthy hair. If you severely lack essential nutrients such as vitamin A, C, D, E, zinc, protein, fatty acids and Biotin, it can lead to hair loss.

With a proper diet, you could have thicker, healthier hair. Keep reading to find out what vitamins are the best for hair growth.

Half of Americans Support Laws Against Weight-Based Discrimination – Everyday Health

June 18th, 2022

Should there be laws in place to protect people with obesity from being denied a job or housing opportunities on the basis of their weight status? Whether or not you answer yes to that question may be influenced by your gender, race, or your own weight, according to a study that examined how these factors impact perceptions of obesity, weight bias, and weight-based discrimination laws.

About half of Americans would support laws against weight-based discrimination, with those who have personally experienced weight bias being about twice as likely to support the policy as people who have not, according to thefindings, which were presented June 7 at the American Society for Metabolic and Bariatric Surgery Annual Meeting (ASMBS)in Dallas.

Weight bias is defined as negative attitudes, beliefs, judgments, stereotypes, and discriminatory acts aimed at people simply because of their weight, according to Obesity Action Coalition (OAC). This can be obvious or subtle, and can happen in any setting work, healthcare, school, and even personal relationships.

What exactly does weight bias look like in practice? Take the case of Taylor v. Burlington Northern Railroad Holdings, Inc. Casey Taylor was an ex-Marine who sued after the railway company made a conditional job offer but then revoked it when a medical exam found his BMI (body mass index) to be in the severely obese range. Taylor was 5 feet 6 inches tall and 256 pounds, which translates to a 41.3 BMI.

A person with a BMI of 25 to 29.9 is considered overweight, and a person with a BMI of over 30 is considered obese. According to the National Heart, Lung, and Blood Institute,BMI is calculated on the basis of a persons weight and height, and the same formula is used for both men and women.

The railway company informed Taylor that it was their policy to not hire anyone who had a BMI over 35; to be able to start work for the railroad, he would need to provide proof of satisfactory health by undergoing several tests (that he would have to pay for out of his own pocket) including a sleep study and an exercise tolerance test, or lose 10 percent of his body weight and keep it off for six months.

Taylor claimed this was a violation of Washington state's Law Against Discrimination. The case made it all the way to the Washington Supreme Court, where the court ruled in favor of Taylor. The court held that obesity is an impairment, and therefore a protected disability.

But statutes like the one in Washington are few and far between, says the senior author of the research,Fatima Cody Stanford, MD, MPH, an associate professor andobesity medicine physician scientist at Massachusetts General Hospital and Harvard Medical School in Boston. There are no universal laws in the U.S. for weight discrimination. With the exception of Washington and Michigan and a few cities, it is legal to discriminate on the basis of weight, she says.

To find out more about peoples perceptions about obesity bias, researchers had a diverse group of 1,888 adults complete a 26-item online questionnaire; the participant makeup was as follows: 328 Asian or Pacific Islander, 404 Hispanic or Latinx, 395 Black, and 761 white. Questions explored issues such as whether or not obesity is a disease, what most Americans think about obesity, awareness of obesity advocacy organizations, and whether or not the participant supported laws against weight discrimination.

About half of Americans overall would back such legislation, and the researchers found there were several major predictors of support or lack thereof. Controlling for other variables, if you personally experienced weight bias, you were twice as likely to support this policy. If you considered obesity to be a disease, you were 1.8 times as likely, says Matt Townsend, MD, the lead author and a resident internal medicine doctor at Duke Health in Durham, North Carolina.

Interestingly, Black race and female gender were each associated with being 1.4 times as likely to support antidiscrimination laws. We can only conjecture that lived experience of stigma is a powerful motivator to make things more equitable, he says.

It makes sense that individuals who have had to navigate race and gender bias are more likely to support laws around weight bias, says Dr. Stanford. These individuals probably face more weight-based discrimination just because of their intersectional identities of being part of a racial/ethnic group, being female, and then having the disease of obesity compounding that, she says.

The American Medical Association (AMA) designated obesity a disease in 2013. Although it is influenced by behavioral factors, experts now recognize that genetics, environment, social determinants of health, and biological factors influenced by medications, illnesses, and hormones all play a role.

Having too much body weight for your height is associated with an increased risk of heart disease, high blood pressure, type 2 diabetes, and even certain cancers. Its estimated that more than two in three U.S. adults have overweight or obesity, according to theU.S. Department of Health and Human Services.

When people have excess weight, other people make many assumptions. They may assume those individuals are lazy, passive, lack self-control, or make poor decisions, says Stanford. We know these biases are not true, but they are widely held beliefs in our society, she says.

Dr. Townsend believes that a problem as culturally ingrained as weight bias needs to be addressed on multiple fronts individual, institutional, and through societal or policy means. At a personal level, it's more awareness on the issue how it creates disparities in attainment, socioeconomic status, and psychological harms, he says.

At the institutional level, organizations can take steps to root out the most common sources of weight stigma, says Townsend. Our study found that the media was the most frequent source of weight bias, but high rates were also experienced in the employment and healthcare sectors, he says. Townsend uses the entertainment industry as an example of how a bias could be recognized and corrected by avoiding the fat-lazy stereotype in movie characters.

Action is also needed at the policy level, he says. The Civil Rights Act of 1964 does not identify weight as a protected condition, and as Stanford notes, laws that prevent weight-based discrimination are the exception, not the rule.

Legislation has the potential to create more equitable protection for people with obesity, and our study showed about half of Americans were supportive of the idea of laws against weight discrimination, says Townsend. These findings could be used to build public support in these natural allies for antidiscrimination legislation, he adds.

Wondering if you have negative assumptions around weight and may be part of the problem? One way to find out is to take the free Harvard implicit association test about weight bias, says Stanford. This can help you discern where you are on the spectrum; if you have biases in this area, then you can begin work on improving that."

Educating yourself can be a good start, she says. The Obesity Action Coalition offers information and resources to help people understand the issue, as well as ways that people can take action to foster positive change.

See the original post here:
Half of Americans Support Laws Against Weight-Based Discrimination - Everyday Health

Recommendation and review posted by Bethany Smith

Female Technology (Femtech) Market to Witness Huge Growth by 2029 |Abcam plc, Active Motif, Inc. Indian Defence News – Indian Defence News

June 18th, 2022

California (United States) The Female Technology (Femtech) Market research report provides all the information related to the industry. It gives the outlook of the market by giving authentic data to its client which helps to make essential decisions. It gives an overview of the market which includes its definition, applications and developments and manufacturing technology. This Female Technology (Femtech) market research report tracks all the recent developments and innovations in the market. It gives the data regarding the obstacles while establishing the business and guides to overcome the upcoming challenges and obstacles.

Get the PDF Sample Copy (Including FULL TOC, Graphs and Tables) of this report @:

https://www.a2zmarketresearch.com/sample-request/280457

Competitive landscape:

This Female Technology (Femtech) research report throws light on the major market players thriving in the market; it tracks their business strategies, financial status and upcoming products.

Some of the Top companies Influencing in this Market include:ALYK, Inc., Aytu BioScience, Inc., Biowink GmbH, Bloomlife, CORA, Flo Health, Inc., Glow, Inc., Inne, Kasha, NaturalCycles Nordic AB, Ovia Health, Plackal Tech, Sustain Natural, The Flex Company, Thinx, Inc., Celmatix Inc., Conceivable Inc., Lia Diagnostics Inc., Lucina Health, Inc., Progny, Inc., Univfy Inc.

Market Scenario:

Firstly, this Female Technology (Femtech) research report introduces the market by providing the overview which includes definition, applications, product launches, developments, challenges and regions. The market is forecasted to reveal strong development by driven consumption in various markets. An analysis of the current market designs and other basic characteristic is provided in theFemale Technology (Femtech) report.

Regional Coverage:

The region wise coverage of the market is mentioned in the report, mainly focusing on the regions:

Get Up to 30% Discount on the first purchase of this report @:

https://www.a2zmarketresearch.com/discount/280457

An assessment of the market attractiveness with regard to the competition that new players and products are likely to present to older ones has been provided in the publication. The research report also mentions the innovations, new developments, marketing strategies, branding techniques, and products of the key participants present in the global Female Technology (Femtech) market. To present a clear vision of the market the competitive landscape has been thoroughly analyzed utilizing the value chain analysis. The opportunities and threats present in the future for the key market players have also been emphasized in the publication.

This report aims to provide:

Table of Contents

Global Female Technology (Femtech) Market Research Report 2022 2029

Chapter 1 Female Technology (Femtech) Market Overview

Chapter 2 Global Economic Impact on Industry

Chapter 3 Global Market Competition by Manufacturers

Chapter 4 Global Production, Revenue (Value) by Region

Chapter 5 Global Supply (Production), Consumption, Export, Import by Regions

Chapter 6 Global Production, Revenue (Value), Price Trend by Type

Chapter 7 Global Market Analysis by Application

Chapter 8 Manufacturing Cost Analysis

Chapter 9 Industrial Chain, Sourcing Strategy and Downstream Buyers

Chapter 10 Marketing Strategy Analysis, Distributors/Traders

Chapter 11 Market Effect Factors Analysis

Chapter 12 Global Female Technology (Femtech) Market Forecast

Buy Exclusive Report @: https://www.a2zmarketresearch.com/checkout

Contact Us:

Roger Smith

1887 WHITNEY MESA DR HENDERSON, NV 89014

[emailprotected]

+1 775 237 4147

See the original post:
Female Technology (Femtech) Market to Witness Huge Growth by 2029 |Abcam plc, Active Motif, Inc. Indian Defence News - Indian Defence News

Recommendation and review posted by Bethany Smith

Women’s Brain Project and Altoida Announce Results Highlighting Sex-Based Differences Using Predictive Digital Biomarker in Alzheimer’s Disease -…

June 18th, 2022

WASHINGTON--(BUSINESS WIRE)--The Womens Brain Project, an international non-profit organization studying gender and sex determinants to brain and mental health and Altoida, a precision neurology company pioneering non-invasive brain health diagnostics using AI and augmented reality (AR), today announced results from a study showing sex-based differences using digital biomarker data collected from Altoidas digital cognitive assessment platform.

Published in EPMA Journal, the study explored sex differences in Altoidas digital cognitive assessment platform in a sample of 568 subjects consisting of a clinical dataset (mild cognitive impairment and dementia due to Alzheimers Disease) and a healthy population. The study results found that a biological sex classifier built on digital biomarker features, captured using Altoidas application, achieved a 75% performance rate in predicting biological sex in healthy individuals, indicating significant differences in neurocognitive performance signatures between males and females.

The discernible differences seem to decline in subjects with mild cognitive impairment (MCI) or overt Alzheimers Disease (AD), independent of age. In the healthy population, the primary differentiating features are micro hand gestures detectable on a wearable, that measured accelerometric data. In this assessment domain, the accuracy reached 80 percent versus the overall neurocognitive Altoida performance. The study found that sex differences can be observed via digital biomarkers, which has the potential to impact diagnosis and treatment of AD.

Our research shows how digital biomarkers can detect sex-based differences which are often overlooked when using standardized cognitive neuropsychological assessment, said Antonella Santuccione Chadha, M.D., CEO and Co-Founder Women's Brain Project and Chief Medical Officer at Altoida. These findings support the need for researchers and drug developers to account for sex-based characteristics in investigating prospective treatments for Alzheimers Disease.

Our ultimate goal is to build an integrated framework for sex-based cognitive assessment to predict, monitor and provide precision treatment of neurodegenerative disease, said Travis Bond, CEO, Altoida. Such a framework could be used for early detection of the disease, and enables both targeted prevention strategies and personalized Alzheimers treatment for patients. By integrating sex with risk stratification based on genetics and individual risk factors with the use of digital biomarker monitoring applications, this will enable the early detection and treatment of symptoms, when a patient has MCI, before development into Alzheimers.

Study results highlight sex-based differences

An MCI diagnosis is determined often later in females, compared to males. This study suggests that using sex-adjusted tools for diagnosis (or sex-adjusted cut-offs) may be needed to improve diagnostic precision. Predictive diagnostics using AD biomarkers in the pre-symptomatic or oligosymptomatic (MCI) stage, followed by targeted preventions and treatment personalized to those individuals considered high risk, are increasingly considered to represent the best chance at successful AD management.

The performance dropped when this classifier was applied to more advanced stages on the AD continuum, including MCI and dementia, suggesting that sex differences might be disease-stage dependent. The results indicate that neurocognitive performance signatures built on data from digital biomarker features are different between men and women. These results stress the need to integrate traditional approaches to dementia research with digital biomarker technologies and personalized medicine perspectives to achieve more precise predictive diagnostics, targeted prevention, and customized treatment of cognitive decline.

The results may also enable researchers to better understand the pathophysiological mechanisms of the disease, which might differ between sexes, with opportunities for personalized treatment. From a predictive medicine perspective, including sex differences might make predictions more precise, especially with algorithms that incorporate multiple variables. In particular, considering sex differences may improve the ability to predict fast decliners in MCI patients, which is a key element for planning therapy and care options. From a precision medicine perspective, whether a patient is a male or female makes a difference, based on the study data. More data on sex differences could guide future clinical practice, informing choices for ad-hoc prevention, diagnosis and treatment options.

These findings should be integrated with the most powerful recent developments in digital medicine to build models of disease development that can fully integrate the effect of sex, digital biomarker technology being one of the most promising tools when developing drugs or digital therapeutics in AD. The study was conducted to show the research community that there are potential sex differences in cognitive testing in Alzheimers, in order to implement measures to mitigate potential biases in clinical application.

Go here to read the rest:
Women's Brain Project and Altoida Announce Results Highlighting Sex-Based Differences Using Predictive Digital Biomarker in Alzheimer's Disease -...

Recommendation and review posted by Bethany Smith

Race Is Often Used as Medical Shorthand for How Bodies Work. Some Doctors Want to Change That. – Kaiser Health News

June 18th, 2022

Several months ago, a lab technologist at Barnes-Jewish Hospital mixed the blood components of two people: Alphonso Harried, who needed a kidney, and Pat Holterman-Hommes, who hoped to give him one.

The goal was to see whether Harrieds body would instantly see Holterman-Hommes organ as a major threat and attack it before surgeons could finish a transplant. To do that, the technologist mixed in fluorescent tags that would glow if Harrieds immune defense forces would latch onto the donors cells in preparation for an attack. If, after a few hours, the machine found lots of glowing, it meant the kidney transplant would be doomed. It stayed dark: They were a match.

I was floored, said Harried.

Both recipient and donor were a little surprised. Harried is Black. Holterman-Hommes is white.

Could a white person donate a kidney to a Black person? Would race get in the way of their plans? Both families admitted those kinds of questions were flitting around in their heads, even though they know, deep down, that its more about your blood type and all of our blood is red, as Holterman-Hommes put it.

Scientists widely agree that race is a social construct, yet it is often conflated with biology, leaving the impression that a persons race governs how the body functions.

Its not just laypeople its in the medical field as well. People often conflate race with biology, said Dr. Marva Moxey-Mims, chief of pediatric nephrology at Childrens National Hospital in Washington, D.C.

Shes not talking just about kidney medicine. Race has been used as a shorthand for how peoples bodies work for years across many fields not out of malice but because it was based on what was considered the best science available at the time. The science was not immune to the racialized culture it sprung from, which is now being seen in a new light. For example, U.S. pediatricians recently ditched a calculation that assumed Black children were less likely to get a urinary tract infection after new research found the risk had to do with a childs history of fevers and past infections not race. And obstetricians removed race and ethnicity from a calculation meant to gauge a patients ability to have a vaginal birth after a previous cesarean section, once they determined it was based on flawed science. Still, researchers say those race-based guidelines are just a slice of those being used to assess patients, and are largely based on the assumption that how a person looks or identifies reflects their genetic makeup.

Race does have its place during a doctors visit, however. Medical providers who give patients culturally competent care the act of acknowledging a patients heritage, beliefs, and values during treatment often see improved patient outcomes. Culturally competent doctors understand that overt racism and microaggressions can not only cause mental distress but also that racial trauma can make a person physically sick. Race is a useful tool for identifying population-level disparities, but experts now say it is not very useful in making decisions about how to treat an individual patient.

Because using race as a medical shorthand is at best imprecise and at worst harmful, a conversation is unfolding nationally among lawmakers, scientists, and doctors who say one of the best things patients can do is ask if and how their race is factored into their care.

Doctors and researchers in kidney care have been active recently in reevaluating their use of race-based medical guidance.

History is being written right now that this is not the right thing to do and that the path forward is to use race responsibly and not to do it in the way that weve been doing in the past, says Dr. Nwamaka Eneanya, a nephrologist with Fresenius Medical Care, who in a previous position with the University of Pennsylvania traced in the journal Nature the history of how race a social construct became embedded in medicine.

The perception that there is such a thing as a Black or white kidney quietly followed patient and donor as Harried and Holterman-Hommes were on the path to the transplant in their medical records and in the screening tests recommended.

Medical records described Harried as a 47-year-old Black or African American male and Holterman-Hommes as a 58-year-old, married Caucasian female. Harried does not recall ever providing his race or speaking with his physicians about the influence of race on his care, but for two years or more his classification as Black or African American was a factor in the equations doctors used to estimate how well his kidneys were working. As previous KHN reporting lays out, that practice distinguishing between Black and non-Black bodies was the norm. In fall 2021, a national committee determined race has no place in estimating kidney function, a small but significant step in revising how race is considered.

Dr. Lisa McElroy, a surgeon who performs kidney transplants at Duke University, said the constant consideration of race is the rule, not the exception, in medicine.

Medicine or health care is a little bit like art. It reflects the culture, she said. Race is a part of our culture, and it shows up all through it and health care is no different.

McElroy no longer mentions race in her patients notes, because it really has no bearing on the clinical care plan or biology of disease.

Still, such assumptions extend throughout health care. Some primary care doctors, for example, continue to hew to an assumption that Black patients cannot handle certain kinds of blood pressure medications, even while researchers have concluded those assumptions dont make sense, distract doctors from considering factors more important than race like whether the patient has access to nutritious food and stable housing and could prevent patients from achieving better health by limiting their options.

Studying population-level patterns is important for identifying where disparities exist, but that doesnt mean peoples bodies innately function differently just as population-level disparities in pay do not indicate one gender is fundamentally more capable of hard work.

If you see group differences theyre usually driven by what we do to groups, said Dr. Keith Norris, not by innate differences in those groups. Still, medicine often continues to use race as a crude catchall, said Norris, a UCLA nephrologist, as if every Black person in America experiences the same amount and the same quantity of structural racism, individualized racism, internalized racism, and gene polymorphisms.

In Harried and Holterman-Hommes case, one striking example of race being used as shorthand for determining how peoples bodies work was an informational guide given to Holterman-Hommes that said African Americans with high blood pressure could not donate an organ, but Caucasians with high blood pressure might still qualify.

I cant believe they actually wrote that down, said Dr. Vanessa Grubbs, a nephrologist at the University of California-San Francisco. That worries Grubbs because using race as a reason to exclude donors can create a situation in which Black transplant recipients have to work harder to find a living donor than others would.

I do think that criteria such as these become barriers for transplantation, said Dr. Rajnish Mehrotra, head of nephrology at the University of Washington. He said that type of hypertension distinction could exclude potential donors like the 56% of Black adults with high blood pressure in the U.S. when more of them are sorely needed.

The inclusion of race did not necessarily affect Harrieds ability to receive a kidney, nor Holterman-Hommes ability to give him one. But following their case offers a glimpse into the ways race and biology are often cemented together.

The St. Louis Case

Harried and Holterman-Hommes met 20 years ago when they worked together at a nonprofit that serves youth experiencing homelessness in St. Louis. Harried was the guy who pulled kids out of their ruts and into a creative mindset, from which they would write poems and songs and do artwork. Holterman-Hommes said he was the calm in their storm. Harried calls Holterman-Hommes big stuff because she is the nonprofits CEO who keeps the lights on and the donations coming in. You never knew that she was the president of the company, said Harried. There wasnt an air about her.

Harried resigned in 2018 as his health declined. Then in 2021, Holterman-Hommes saw a KHN article about Harried and decided to see if she could help her former colleague. Although Holterman-Hommes mother was born with one kidney, she had lived a long and healthy life, so Holterman-Hommes figured she could spare one of her own.

As Holterman-Hommes explored becoming a donor candidate, initial tests showed high blood pressure readings, in addition to lower-than-ideal kidney function. But I like to get an A on a test, she said, so she redid both sets of tests, repeating the kidney function test after staying better hydrated and the blood pressure test after a big work deadline had passed. She moved on in the screening process after her results improved.

Grubbs wonders whether, if Holterman-Hommes had been Black, they would have just dismissed her. Grubbs shared an instance in which she suspects thats exactly what happened to the wife of a patient of hers in California who needed a kidney transplant.

The wife, who is Black and was in her 50s at the time, wasnt allowed to give the patient a kidney because of her hypertension.

There are people in this country that will tell you that, Oh, white people donate kidneys, Black people dont donate kidneys, and thats not true, said Mehrotra. You hear that racist trope. But [there are] all of these barriers to kidney donation.

Barnes-Jewish Hospital later said it had given Holterman-Hommes an outdated guide, an unfortunate circumstance that is being corrected, and provided a new one that does not say Black people with hypertension cannot donate. Instead, it says that people cannot donate if they have hypertension that was either diagnosed before age 40 or requires more than one medication to manage.

But at some point, it was a policy, said Harried, whose kidneys have been failing for several years. And its unclear how many years that outdated guidance shaped perceptions among those seeking care at Barnes-Jewish, which performs more living-donor kidney transplants per year than any other location in Missouri, according to the Scientific Registry of Transplant Recipients.

There is little transparency into how medical centers incorporate race into their decision-making and care. Guidelines from the United Network for Organ Sharing, the national organization in charge of the transplant system, leave the door open for hospitals to exclude a donor with any condition that, in the hospitals medical judgment, causes the donor to be unsuitable for organ donation.

Tanjala Purnell, an epidemiologist at the Johns Hopkins Bloomberg School of Public Health studying disparities in kidney transplantation, said she knows of several centers that used race-based criteria, though some have relaxed those rules, instead deciding case by case. Theres not a standard set to say, Well, no, you can absolutely not have different rules for different people, she said. We dont have those safeguards. Dr. Tarek Alhamad, medical director of the kidney program at the Washington University and Barnes-Jewish Transplant Center, said race-based criteria for kidney donations arent created to exclude Black people it was born of a desire to avoid harming them.

African Americans are more likely to have end-stage renal disease, they are more likely to have end-stage renal disease related to hypertension. And they are more likely to have genetic factors that would lead to kidney dysfunction, said Alhamad.

Compared with white and Hispanic donors, non-Hispanic Black donors are known to be at higher risk for developing kidney failure because of their donation, though its still very rare.

He said it feels unethical to take a kidney from someone who may really need it down the line. This is our role as physicians not to do harm.

The Science

Researchers are studying a possible way to clarify who is really at risk in donating a kidney, by identifying specific risk factors rather than pinning odds on the vague concept of race.

Specifically, a gene called APOL1 could influence a persons likelihood of developing kidney disease. All humans have two copies of this gene, but there are different versions, or variants, of it. Having two risk variants increases the chance of kidney injury.

The risk variants are most prevalent in people with recent African ancestry, a group that crosses racial and ethnic boundaries. About 13% of African Americans have the double whammy of two risk variants, said Dr. Barry Freedman, chief of nephrology at the Wake Forest School of Medicine. Even then, he said, their fate isnt sealed most people in that group wont get kidney failure. We think they need a second hit, like HIV infection, or lupus, or covid-19.

Freedman is leading a study that looks, in part, at how kidney donors with those risk variants fare in the long term.

This is really important because the hope is that kidneys wont be discarded or turned down as frequently, said Moxey-Mims, who is also involved in the research.

Researchers who are focused on health equity say that while APOL1 testing could help separate race from genetics, it could be a double-edged sword. Purnell pointed out that if APOL1 is misused for example, if a transplant center makes a blanket rule that no one with two risk variants can donate, rather than using it as a starting point for shared decision-making, or if doctors offer the test based only on a patients looks it could merely add another criterion to the list by which certain people are excluded.

We have to do our due diligence, said Purnell, to ensure that any effort to be protective doesnt end up making the pool of available donors for certain groups smaller and smaller and smaller. Purnell, McElroy, and others steeped in transplant inequities say that as long as race which is a cultural concept defining how someone identifies, or how they are perceived is used as a stand-in for someones ancestry or genetics, the line between protecting and excluding people will remain fuzzy.

Thats the heart of the matter here, said McElroy.

So where does race belong in kidney transplant medicine? Many of the physicians interviewed for this article many of them people of color said it primarily serves as a potential indicator of hurdles patients may face, rather than as a marker of how their bodies function.

For example, McElroy said she might spend more time with Black patients building trust with them and their families, or talking about how important living donations can be, similar to the ways she might spend more time with a Spanish-speaking patient making sure they know how to access a translator, or with an elderly patient emphasizing how important physical activity is.

The purpose is not to ignore the social determinants of health of which race is one, she said. Its to try to help them overcome the race-specific or ethnicity-specific barriers to receiving excellent care.

While all the science gets sorted out, Eneanya is trying to get the message out to patients: Just ask the question: Is my race being used in my clinical care? And if it is, first of all, what race is in the chart? Is it affecting my care? And what are my options?

Just keep your eyes open, ask questions, said Harried.

In late April, a kidney from Holterman-Hommes body was successfully placed into Harrieds. Both are home now and say they are doing well.

Rae Ellen Bichell: rbichell@kff.org,@raelnb

Cara Anthony: canthony@kff.org,@CaraRAnthony

Original post:
Race Is Often Used as Medical Shorthand for How Bodies Work. Some Doctors Want to Change That. - Kaiser Health News

Recommendation and review posted by Bethany Smith

The "Age" Of Your Sperm Could Predict Your Chances Of Pregnancy – Fatherly

June 18th, 2022

Measuring how old a persons sperm is could help predict the chances of them getting pregnant, according to a new study. But sperms age isnt just how many birthdays its had. It takes about 64 days for a sperm cell to mature, and depending on how much sex youre having (or how much youre masturbating), its released into the world shortly thereafter. But a sperms age has nothing to do with that cycle. Instead, it has to do with the aging process that occurs at the cellular level. And that biological age is linked to how long it takes a couple to conceive.

Chronological age, or how much time a person has lived, is an important factor when it comes to pregnancy especially for pregnant people, who have a finite number of egg cells. But it doesnt tell the whole story.

All your friends from high school, they're the same age, right? says J. Richard Pilsner, Ph.D., director of Molecular Genetics and Infertility at Wayne State University in Detroit, Michigan, and lead author of the study. But that number doesn't capture some of the genetic differences they have or environmental factors like smoking or exercising, which can have major impacts on the aging process, Pilsner says.

Chronological age is actually somewhat of an arcane way of thinking about aging. If we have a precise measurement of the biological age, that's going to give us more information, he says.

Thats why his team developed a novel technique to read the true biological age of sperm cells. They measured this age by reading how much DNA methylation a sperm cell has how many of a type of chemical called methyl groups are attached to the sperms DNA, which alters how its genes are expressed. The more methylation, the older the sperm. Using this method, the researchers can tell whether sperms biological age is up to nine years younger or older than its makers chronological age.

Pilsner and his team used this technique to analyze the sperm of 379 people from 16 different locations across the U.S. from 2005 to 2009, then followed the participant couples for up to 12 months or until they got pregnant. They compared the sperms biological age against the ability of the couple to get pregnant. Couples with older sperm took 17% longer to get pregnant than people with younger sperm.

17%

How much longer it took people with older sperm to get their partners pregnant compared to people with younger sperm.

A sperms biological age can match up with a persons chronological age, but it doesnt necessarily have to. A man could be 30 years old, but his sperm's epigenetic age may be 35, and that's causing a lower pregnancy probability, Pilsner says.

Lifestyle choices can advance the biological aging of sperm. For example, the study found that men who smoked had older sperm.

Pilsner will be conducting more research on what can speed up or slow down sperm aging in the coming months, but he notes that the basics of a healthy lifestyle, sleep, diet, and exercise are important for ensuring that your cells dont mature too quickly. Future research could also shed light on whether sperms age affects the babys health.

Knowing sperms true age could also help couples get pregnant faster. If a person has very old sperm, for example, they may decide to look into assisted reproductive technology sooner.

There's very little screening for male reproductive health, Pilsner says. He hopes that the new technique for determining sperms age could one day help doctors diagnose clinical infertility, given that the semen parameters currently used have been shown to be poor predictors of reproductive success. We need this new biomarker that really captures what's happening biologically within the cell, he says.

The next step? After validating these findings, Pilsners lab will run experiments on mice to see whether there could be pharmacological options for rejuvenating older sperm cells. One day, its possible that men having trouble getting their partners pregnant could turn back the clock on their sperm to increase their chances of getting pregnant.

Not subscribed to Fatherlys newsletter yet? Were not mad, just disappointed.

Originally posted here:
The "Age" Of Your Sperm Could Predict Your Chances Of Pregnancy - Fatherly

Recommendation and review posted by Bethany Smith

The Average Calf Size for Men and Women Fitness Volt – Fitness Volt

June 18th, 2022

Calves are one of the most stubborn muscle groups. Many people find it hard to make them grow, irrespective of how hard or often they train them in the gym.

Are big calves only for improving your physique aesthetics? Not really.

A study conducted on 6,265 people found that the bigger a persons calves, the smaller their risk of stroke. Regardless of age, sex, body mass index, and other vascular risk factors, those with bigger calves had fewer fatty deposits known as plaques built up in their arteries. It means they have a lower risk for stenosis, carotid artery disease, and strokes. [1]

If you do not wear shorts to the gym as you fear ridicule because of your tiny calves, you have come to the right place. In this article, youll learn about the average calf size for men and women of different ages, how to measure your calf circumference correctly, and how to increase your calf size.

Youve probably heard of the unwritten rules you should never ask a woman her age, a man his salary, and agym bro his calf size. Okay, we just came up with the calf size part, but make no mistake, it can be even more offending than the first two questions.

Your calf size is determined by your genetics and daily activity levels, especially if youre not a gym regular. You could alter your calf circumference with calf exercises, but it requires hard work in the gym.

According to data based on a sample of 4,303 men aged 20 years and above, the Center for Disease Control and Prevention (CDC)suggests that the average male calf size is15.5 inches. [2]

On average, men between 20 and 29 had 15.5-inch calves, while men aged 30 to 39 had 15.6-inch calves. Average male calf circumference peaks at15.8 inchesfor the40 to 49 age group.

Although men undergo a gradual increase in calf size up to the age of 49, the drop in calf circumference is comparatively drastic. Per the survey, men between 50 and 59 have 15.6-inch calves. It drops down to 15.4 inches by the time they enter their 60s.

In their 70s, men, on average, have 14.9-inch calves, which further drops to 14.2 inches by the time they are in their 80s.

Related:Ronnie Coleman Hits Calf Raises for Reps: Trying My Very Best with My Feet Totally Numb

Per the same CDC research cited above (based on the sample size of 4,133 women aged 20 and above), the average female calf size is 15 inches. [2]

For women between the ages of 20 to 29, the average calf size is 14.8 inches. It increases to 15.2 inches for women between 30 and 39 before peaking at15.4 inchesfor females aged between40 and 49.

After peaking around 50, womens calf size, on average, decreases to 15.1 inches between the age of 60 and 69. The calf size drops to 14.4 inches as women enter their 70s and hits its low at 13.9 inches in their 80s.

Although men have larger calves than their counterparts of the same age, the difference isnt as big as some might have imagined. Notably, age plays an important role in determining your calf size.

Related:The 13 Best Calf Raise Machine Alternatives for Bigger, Stronger Lower Legs

There are a few different ways of measuring your calf size. Some people like to get their calves measured while seated, while others prefer doing it standing. Calf measurements taken seated are usually bigger than those recorded standing up.

Like in the case of other muscle groups like the biceps and chest, many people like to get their calves measuredafter they have a good muscle pumpfrom performing a few sets of the lower leg exercises.

Nonetheless, it does not matter if you choose to get your calves measured standing or seated, with or without a pump, or contracted or relaxed. Make sure you do it in the same position every time for consistency.

Here is how to measure your calves correctly:

Competitive bodybuilding is a game of aesthetics, symmetry, and illusions. You do not have to build your calves to a certain size to be able to win bodybuilding shows. However, you should focus on building proportions and balance.

Arnold Schwarzenegger summed it up the best when he said

When I went to train with my hero, Reg Park, he pulled out a tape measure and measured my calves and biceps. He said, Arnold, your calves are 19 inches, and your biceps are 21 inches. You might win Mr. Universe like this, but youll never go all the way. You need to build up your calves. Every step you take is a 250-pound calf raise. So to grow, you are going to have to go as heavy as possible, and youre going to need to do 10-15 sets every single day.'

If you are a bodybuilding fan, make sure your calves are as big as your biceps. If your upper arms are bigger than your lower legs, your body might appear disproportionate.

Check Out:14 Best Legs in Bodybuilding History

Building bigger calves is easier said than done. Youll have to undergo strict training, diet, and recovery regimen to put muscle mass on your lower legs. Here is an effective calf training workout you should try the next time you hit the gym:

Next Read:15 Ways To Turn Your Calves Into Full Grown Bulls

If your calves are slightly over or under (up to 0.3 inches, either way) the average size for your age and gender, your calves will still be considered normal. However, if your calves are smaller, you should follow the workout listed above to add mass to your lower legs.

For men of average height (five-foot-nine) and weight (194.7 pounds), 16-inch calves or bigger can be considered big. On the other hand, 15.5-inch or bigger calves can be considered big for women of average height (five-foot-four) and weight (170.6 pounds). [2]

Knowing the average calf size for your age and gender gives you a good idea of where you stand in terms of your lower leg gains.

If you want to add size to your calves, you should add the workout mentioned above to your training regimen and follow a high-protein diet. On the other hand, you should switch to acalorie-deficit dietand spike your cardiovascular workouts to lose a few inches off your lower legs.

View original post here:
The Average Calf Size for Men and Women Fitness Volt - Fitness Volt

Recommendation and review posted by Bethany Smith

Clues to bee health found in their gut microbiome – EurekAlert

June 18th, 2022

image:Small carpenter bee on a flower. view more

Credit: York University

TORONTO, June 17, 2022 The local environment plays a pivotal role in the health and diversity of the gut microbiome of wild bees which could help detect invisible stressors and early indicators of potential threats, say York University scientists in a new study.

Piloting a new frontier of metagenomics, the researchers sequenced whole genomes of three species of carpenter bees, a type of wild bee, in North America, Asia and Australia. This analysis allowed them to gain insights into the bees gut microbiome (bacteria and fungi), diet and viral load, as well as their environmental DNA.

Unlike social bees (like honeybees and bumblebees), the researchers found solitary bees get their microbiome, which is important for health, from their environment where they forge for food, rather than inheriting it from their nest mates. Carpenter bees burrow into woody plant stalks to lay eggs rather than in hives.

This may make them better bio-indicators as they are much more sensitive to their environment, says Faculty of Science Associate Professor Sandra Rehan, corresponding author of the research, Comparative metagenomics reveals expanded insights into intra- and interspecific variation among wild bee microbiomes, published today in the journal CommunicationsBiology.

In Australia, the local populations had highly distinctive metagenomes and microbiomes; so much so that machine learning tools were able to reliably predict from which population each bee was drawn.

The research team also discovered crop pathogens in the microbiomes of carpenter bees which were previously only found in honeybees.

These pathogens are not necessarily harmful to bees, but these wild bees could potentially be vectoring diseases that might have negative effects on agriculture, says Rehan. Finding out how these pathogens are spreading in wild bees is important as bees contribute to ecological and agricultural health worldwide in addition to more than $200 billion in annual agricultural services.

Establishing a baseline of what a healthy microbiome looks like in wild bees allows scientists to compare species across continents and populations, and to figure out how diseases and harmful microbiota are being introduced and transmitted.

We can really dissect bee health in a very systematic way looking at population genetics and parasite pathogen loads, healthy microbiomes and deviations, says Rehan, whose Postdoctoral Research Associate, Wyatt Shell, led the study. The long-term goal is really to be able to use these tools to be able to also detect early signatures of stress and habitats in need of restoration or conservation. To develop it almost like a diagnostic tool for bee health.

Researchers believe they have captured the core microbiome of carpenter bees for the first time. They found beneficial bacteria in all three carpenter bee species which helped with metabolic and genetic functions. They also detected species of Lactobacillus, which is an essential beneficial bacteria group, imperative for good gut health and found across most bee lineages. Lactobacillus may protect against prevalent fungal pathogens, boost the immune system, and facilitate nutrient uptake.

However, a recently published paper in the journal Environmental DNA by Rehan and her graduate student Phuong Nguyen, Developmental microbiome of the small carpenter bee, Ceratina calcarata, which studied the microbiome in brood and adult carpenter bees in cities, found they were lacking Lactobacillus.

This raises red flags, says Rehan. We are continuing those studies to look at more nuanced urban, rural comparisons and long-term data to really understand these environmental stressors. Anytime we characterize a microbiome and see deviations from what we know to be normal, it can give us an indication of a population or species in threat.

Overall, the results show metagenomic methods could provide important insights into wild bee ecology and health going forward.

We've been piloting this research approach in a few species, but we're aiming to study dozens of wild bee species and broader comparisons are coming. These two studies are really establishing the foundation," she says. The long-term goal is really to be able to use these tools to detect early signatures of stress in wild bees and thereby identify habitats in need of restoration or preservation. We are excited to be building the tools for a new era of wild bee research and conservation.

The work was funded by NSERC Discovery Grants, Weston Family Foundation Microbiome Initiative funds, and the NSERC E.W.R. Steacie Memorial Fellowship to Rehan.

PHOTOS: Small carpenter bee - https://www.yorku.ca/news/wp-content/uploads/sites/242/2022/06/860-header-Small-carpenter-bee.jpg

Male carpenter bee (certina calcarata) - https://www.yorku.ca/news/wp-content/uploads/sites/242/2022/06/Male-ceratina-calcarata-side-copy-scaled.jpg

Carpenter bee (ceratina australensis) nest - https://www.yorku.ca/news/wp-content/uploads/sites/242/2022/06/Ceratina_australensis_nest.jpg

Carpenter bee (ceratina japonica) - https://www.yorku.ca/news/wp-content/uploads/sites/242/2022/06/Ceratina-japonica.jpg

###

York Universityis a modern, multi-campus, urban university located in Toronto, Ontario. Backed by a diverse group of students, faculty, staff, alumni and partners, we bring a uniquely global perspective to help solve societal challenges, drive positive change and prepare our students for success. York's fully bilingual Glendon Campus is home to Southern Ontario's Centre of Excellence for French Language and Bilingual Postsecondary Education. Yorks campuses in Costa Rica and India offer students exceptional transnational learning opportunities and innovative programs. Together, we can make things right for our communities, our planet, and our future.

Media Contact:Sandra McLean, York University Media Relations, 416-272-6317,sandramc@yorku.ca

Communications Biology

Animals

Comparative metagenomics reveals expanded insights into intra- and interspecific variation 2 among wild bee microbiomes

17-Jun-2022

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.

Go here to see the original:
Clues to bee health found in their gut microbiome - EurekAlert

Recommendation and review posted by Bethany Smith

How Nature Solved the Problem of Too Much DNA – Office for Science and Society

June 18th, 2022

When you consider how babies are made, you bump up against a basic math problem. No need for calculus here, or even the mental gymnastics of carrying the one. Its a problem of doubling.

A mother has 23 pairs of chromosomes. A father also has 23 pairs of chromosomes. When sperm meets the egg, you would expect the embryo, and thus the fetus, and thus the baby to have 46 pairs of chromosomes. And when that baby grows up, one of its eggs, filled with 46 pairs of chromosomes, might meet-cute a sperm, carrying its own 46 pairs of chromosomes, and the result would be a baby whose cells hold onto 92 pairs of chromosomes.

Given humanitys long history on this planet and its propensity to make babies, our cells would have, by now, exploded with chromosomal goo. This surplus of DNA would be unmanageable from a containment perspective, let alone what it would do to the body. We simply do not need that much DNA. When we have one extra chromosome, such as in trisomy 21, the effects are appreciable. What would happen if we had dozens upon dozens of extra chromosomes, or hundreds?

In order to figure out natures answer to this quandary, someone needed to crawl under the metaphorical bed sheets and figure out just how babies are made. That man was Oscar Hertwig, and the procreators that captured his attention were spiny globules we call sea urchins.

Hertwig was born in 1849 in Friedberg, Germany. He and his brother Richard, one year his junior, attended university together, and Oscars curiosity was later piqued by the question of just what happened when a sperm cell and an egg cell met. Two main theories were fighting it out in academic circles at the time. The first was that the sperm touched the egg and basically vibrated against it, which spurred the egg into becoming an embryo. In this scenario, sperm was a sort of alarm clock loudly buzzing and prodding the egg to wake up and fulfill its destiny.

The second hypothesis was that the sperm penetrated the egg and their raw materials mixed and became the embryo.

Hertwig saw the evidence that had been published for this second theory but was not happy with it. When he heard that his brother was leaving for the Mediterranean to work on a research project with the preeminent biologist they had both studied under, Oscar decided to join them. And he made an important observation while there: sea urchins, which can be found on the Mediterranean seashore, had transparent embryos.

With the veil of fertilization thus lifted, Hertwig was able to witness sea urchin sperm entering a sea urchin egg cell and fusing with its nucleus, which contains the chromosomes. Sperm was no alarm clock; it mixed with the egg. Once a single sperm cell had penetrated the egg, a force field called the vitelline membrane was erected by the egg to block out the remaining sperm cells.

This is now common knowledge, but what Hertwig didnt know then was exactly what was happening to the contents of the sperm and egg when they met and what strange chromosomal dance had taken place before the sperm and egg were even created. Because that would prove to be the answer to the problem of DNA doubling up all the time.

Lets start with sperm, the simpler of the two.

Inside the testis of an adolescent male, we look for a regular cell that is about to become a sperm cell. We race past the complex structures that bring this dynamic cell to life and enter its nucleus, the command center of the cell which contains the chromosomes. We focus on chromosome 1. There are two of them, joined at the hip. Lets call them Dwayne and Matthew. Matthew was inherited from the teenage boys mom (hence the M" name), while Dwayne was a gift from his dad. They are, in a manner of speaking, fraternal twins: the same age, with similar enough features, but with important differences.

Cells, which contain Dwayne and Matthew and nearly two dozen other pairs of chromosomes, divide, like a soap bubble being pinched into two. In order to make sure that the cells that result from this division both carry Dwayne and Matthew, Dwayne and Matthew need to be copied.

And so, through the magic of molecular biology, Dwayne and Matthew, joined at the hip, find themselves next to Dominic and Marc, also joined at the hip and looking like clones of Dwayne and Matthew. We have now doubled the amount of DNA inside this cell in preparation for that bubble pinch.

But before this can happen, a critical event takes place. It does not happen in any other cell of the boys body, but strictly in those that are to become sperm cells.

Matthew, originally inherited from Mom, and Dominic, a copy of Dwayne which was inherited from Dad, get together. Its not exactly love, but more akin to one of Dr. Frankensteins experiments. A part of Matthew goes to Dominic and vice versa, creating new chromosomes: Matthinic and Domew.

What happens next is simple. Dwayne and the new chromosome Matthinic move to one end of the cell, while Domew and Marc shuffle over to the other side. The cell splits into two, and these cells then each split into two, creating four sperm cells.

There is a name for this entire process of a cell swapping material between Mommys and Daddys chromosomes after it has doubled up its DNA, then twice halving its content. Its called meiosis (pronounced my-OH-sis) and it means a lessening. It takes place in cells that are meant to become sex cells, i.e. sperm and egg in humans.

Figure 1: A simplified illustration of meiosis, using the development of sperm cells as an example. 1) Each chromosome consists of two halves, one inherited from Daddy (labelled Dwayne here) and the other inherited from Mommy (labelled Matthew), and identical copies of them are made at the beginning of this process (Dominic and Marc). 2) One of the halves inherited from Mommy swaps material with one of the halves inherited from Daddy. 3) This creates new recombinant chromosomes. 4) Eventually, each one of these chromosomes finds itself in a single sperm cell. Created with BioRender.com.

Cells which contained both Dwayne and Matthew now only contain either Dwayne or a modified version of Matthew. Where once there were two chromosomes 1 in the same cell, there is now only one. The same process concurrently affects chromosomes 2 to 22 and the sex chromosomes as well. Sperm cells thus have half as much DNA as any other cell in the body.

Meiosis also takes place in females, though the process stops-and-goes over the course of many years to eventually create egg cells that also contain half as much DNA as any other cell. (To be more accurate, some cells in our body actually contain even more DNA than regular cells, for example up to half of our liver cells.)

This is why, when a sperm penetrates an egg, we do not get 46 pairs of chromosomes.

The 23 single chromosomes of the sperm are matched with the 23 single chromosomes of the egg, and this creates a new combination of 23 pairs of chromosomes in the embryo. Only Dwayne becomes part of the embryo, or Marc, or Matthinic, or Domew, or any one of a near-infinite combination of Matthew and Dominic chromosomes, or of Dwayne and Marc recombined chromosomesall depending on which sperm wins the race.

And the egg they will fertilize will contain May, or Dawn, or Darilyn, or Marlene, or any combination of Marilyn and Darlene and of May and Dawn.

And these recombinationscreating Matthinics and Darilynsare critical events because they engender genetic diversity. Without these DNA swaps, the same chromosomes would get passed down, intact, from generation to generation. Instead, a mothers and fathers genetic contributions are scrambled inside their children when the latter start making sexual cells. This diversity benefits us: it gives us a better chance to survive when our environment changes and helps reduce the chances of our children inheriting certain genetic diseases. And this perk is not just for us. Meiosis takes place in plants and animals more broadly.

One of the core principles of toxicology is that its the dose that makes the poison. In a way, it holds true in genetics. We could not withstand a growing accumulation of chromosomes from generation to generation. Meiosis is thus key in keeping the number of chromosomes constant and helping ensure diversity.

Take-home message:- Without a special process in place, every child would receive all of its mothers and fathers DNA and thus end up with twice as much DNA as each parent- What actually happens is that sperm cells and egg cells wind up with half of the DNA of regular cells through a process called meiosis- During meiosis, equivalent chromosomes inherited from different parents swap parts of each other, which contributes to genetic diversity

@CrackedScience

Read the rest here:
How Nature Solved the Problem of Too Much DNA - Office for Science and Society

Recommendation and review posted by Bethany Smith

A New Standard of Care? Enhertu Improves Survival in People With Metastatic HER2-Low Breast Cancer – Breastcancer.org

June 9th, 2022

Compared with doctors choice of chemotherapy, Enhertu (chemical name: fam-trastuzumab-deruxtecan-nxki) improved both progression-free survival and overall survival in people diagnosed with previously treated metastatic HER2-low breast cancer, according to a study.

The research was presented on June 5, 2022, at the American Society of Clinical Oncology (ASCO) Annual Meeting and published simultaneously in The New England Journal of Medicine. Read the abstract of Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer.

Progression-free survival is how long a person lives without the cancer growing. Overall survival is how long a person lives, whether or not the cancer grows.

Metastatic breast cancer is breast cancer that has spread to parts of the body away from the breast, such as the bones, liver, or brain.

Some breast cancer cells make, or overexpress, too many copies of the HER2 gene. The HER2 gene makes a protein known as a HER2 receptor. HER2 receptors are like ears, or antennae, on the surface of cells. These HER2 receptors receive signals that stimulate the cell to grow and multiply. But breast cancer cells with too many HER2 receptors can pick up too many growth signals and start growing and multiplying too much and too fast. Breast cancer cells that overexpress the HER2 gene are called HER2-positive.

Doctors use several tests to find out if a breast cancer is HER2-positive. Two of the most common are:

IHC (ImmunoHistoChemistry): The IHC test uses a chemical dye to stain the HER2 proteins. The IHC measures the amount of HER2 proteins on the surface of cells in a breast cancer tissue sample and gives it a score of 0 to 3+. If the score is 0 to 1+, its considered HER2-negative. If the score is 2+, its considered borderline. A score of 3+ is considered HER2-positive.

FISH (Fluorescence In Situ Hybridization): The FISH test uses special labels that attach to the HER2 proteins. The special labels have chemicals added to them so they change color and glow in the dark when they attach to the HER2 proteins. With the FISH test, you get a score of either positive or negative (some hospitals call a negative test result zero).

About 15% to 20% of breast cancers are HER2-positive. Still, research shows that more than 60% of breast cancers considered HER2-negative have some HER2 proteins on the surface of its cells. There just arent enough HER2 proteins for the cancer to be considered HER2-positive. Doctors now call these cancers HER2-low.

There are medicines called targeted therapies that specifically target the HER2 receptors on HER2-positive breast cancer cells. Herceptin (chemical name: trastuzumab) was the first anti-HER2 medicine developed. Still, these anti-HER2 medicines have not been effective against HER2-low breast cancers.

HER2-low breast cancer is commonly treated as if it were HER2-negative breast cancer, almost always with chemotherapy.

Enhertu is approved by the U.S. Food and Drug Administration (FDA) to treat unresectable or metastatic HER2-positive breast cancer in people who have previously received an anti-HER2 medicine:

for metastatic disease

before or after surgery for early-stage disease that came back (recurred) within six months of completing treatment

Unresectable means the cancer cant be removed with surgery.

Enhertu is a targeted therapy made up of three parts:

fam-trastuzumab: an anti-HER2 medicine that has the same basic structure as Herceptin

a topoisomerase I inhibitor chemotherapy called DXd: topoisomerase I inhibitors work by interfering with a cancer cells ability to replicate

a compound that links the fam-trastuzumab molecule to the topoisomerase I inhibitor chemotherapy molecule

Doctors call Enhertu an antibody-drug conjugate targeted therapy. The combination of the topoisomerase I inhibitor and the linking compound is called deruxtecan. The linking compound attaches (conjugates) the fam-trastuzumab to the topoisomerase I inhibitor chemotherapy.

Enhertu was designed to deliver the topoisomerase I inhibitor to cancer cells in a targeted way by attaching the topoisomerase I inhibitor to the fam-trastuzumab. The fam-trastuzumab part of Enhertu attaches to the HER2 protein, stopping it from receiving growth signals and also carries the topoisomerase I inhibitor to the cancer.

Because Enhertu contains both an anti-HER2 medicine and a chemotherapy medicine, the researchers for this study thought it might effectively treat HER2-low breast cancers.

Called DESTINY-Breast04, the study included 557 people 555 women and two men diagnosed with metastatic HER2-low breast cancer. The people joined the study between December 2018 and December 2021. All the people in the study had already received one or two lines of chemotherapy for metastatic disease.

In this study, the researchers defined breast cancer as HER2-low if it got an IHC score of 1+ or an IHC score of 2+ and a negative FISH test.

About 89% of the cancers in the study were hormone receptor-positive and about 11% were hormone receptor-negative.

About 45% of the people in the study lived in Europe or Israel and almost half were white.

The researchers randomly assigned the people to one of two treatment groups:

373 people received Enhertu; 331 (88.7%) of these people had hormone receptor-positive disease

184 people received their doctors choice of chemotherapy; 163 (88.6%) of these people had hormone receptor-positive disease

Among people who received their doctors choice of chemotherapy medicines:

51.1% received Halaven (chemical name: eribulin)

20.1% received Xeloda (chemical name: capecitabine)

10.3% received Abraxane (chemical name: albumin-bound or nab-paclitaxel)

10.3% received Gemzar (chemical name: gemcitabine)

8.2% received Taxol (chemical name: paclitaxel)

About 63% of people who received Enhertu and 61% of people who received their doctors choice of chemotherapy had previously received three or more types of treatment for metastatic disease.

The researchers followed about half the people for more than 18.4 months and half for less time.

As of Jan. 11, 2022, progression-free survival time was:

9.9 months for people who received Enhertu

5.1 months for people who received their doctors choice of chemotherapy

Overall survival time was:

23.4 months for people who received Enhertu

16.8 months for people who received their doctors choice of chemotherapy

The researchers also looked at specific subgroups of people in the study.

For people diagnosed with hormone receptor-positive disease:

progression-free survival was 10.1 months for people who received Enhertu and 5.4 months for people who received their doctors choice of chemotherapy

overall survival was 23.9 months for people who received Enhertu and 17.5 months for people who received their doctors choice of chemotherapy

For people diagnosed with hormone receptor-negative disease:

progression-free survival was 8.5 months for people who received Enhertu and 2.9 months for people who received their doctors choice of chemotherapy

overall survival was 18.2 months for people who received Enhertu and 8.3 months for people who received their doctors choice of chemotherapy

The researchers analyzed side effects in 371 people who received Enhertu and 172 people who received their doctors choice of chemotherapy.

More than 99% of the people who received Enhertu and more than 98% of people who received their doctors choice of chemotherapy had at least one side effect. About a quarter of the people in each treatment group had a serious side effect.

About 16% of people who received Enhertu and about 8% of people who received their doctors choice of chemotherapy stopped the medicine because of side effects.

The most common side effects of any grade among people receiving Enhertu were:

nausea, experienced by 73% of the people

fatigue, experienced by 47.7% of the people

hair loss, experienced by 37.7% of the people

The most common grade 3 or higher side effects among people receiving Enhertu were:

low white blood cell count, experienced by 13.7% of the people

low red blood cell count, experienced by 8.1% of the people

fatigue, experienced by 7.5% of the people

Interstitial lung disease, a general term for disorders that cause inflammation and scarring in the lungs, is a less common but serious side effect of Enhertu. Overall, 45 people who received Enhertu and one person who received the doctors choice of chemotherapy developed interstitial lung disease.

In the person who received the doctors choice of chemotherapy, the interstitial lung disease was grade 1.

Among the people who received Enhertu:

13 people had grade 1 interstitial lung disease

24 people had grade 2 interstitial lung disease

5 people had grade 3 interstitial lung disease

3 people had grade 5 interstitial lung disease

Overall, 14 people who received Enhertu and five people who received their doctors choice of chemotherapy died from drug-related causes during the study.

With these results, we have expanded the benefits of HER2 targeted therapy to a new population of breast cancer patients, said lead author Shanu Modi, MD, breast medical oncologist at Memorial Sloan Kettering Cancer Center when presenting the research. And [we] have established trastuzumab deruxtecan as the new standard of care for patients with HER2-low metastatic breast cancer. These findings have the potential to impact survival for approximately 50% of all patients diagnosed with metastatic breast cancer today.

If youve been diagnosed with metastatic breast cancer, the results of this study are extremely exciting and promising.

The attendees at the 2022 ASCO Annual Meeting were also excited. At the end of her presentation, Dr. Modi received a 40-second standing ovation.

The results of DESTINY-Breast04 are practice-changing, Dr. Modi said in an interview after her presentation. I think the strong efficacy of trastuzumab deruxtecan in this HER2-low patient population supports the need to now reclassify HER2-low as a new therapeutically targetable category of metastatic breast cancer.

Based on the results of the DESTINY-Breast04 study, you may want to talk to your doctor about the HER2 test results in your pathology report. If the score was 1+ on an IHC test or the score was 2+ on an IHC test plus a negative FISH test, Enhertu may be an option for you.

Learn more about Enhertu.

Written by: Jamie DePolo, senior editor

The rest is here:
A New Standard of Care? Enhertu Improves Survival in People With Metastatic HER2-Low Breast Cancer - Breastcancer.org

Recommendation and review posted by Bethany Smith

Deadly cancer quickly shrinks by 50% with ‘one-and-done’ therapy: study – New York Post

June 9th, 2022

An experimental therapy has given one pancreatic cancer patient hope for new life.

Thanks to a one-and-done treatment, the 71-year-old womans metastatic cancer was reduced by 50% in just one month, according to her doctors. After six month, her tumors has shrunk by nearly three-quarters.

A case study about her remarkable cancer journey was published on Thursday in the New England Journal of Medicine.

Kathy Wilkes, of Ormond Beach, Florida, was diagnosed with aggressive pancreatic cancer in 2018. She underwent eight rounds of chemotherapy and an operation to remove part of her pancreas, but her cancer continued to spread into her lungs within a year.

Pancreatic cancer is one of the deadliest forms of the disease, with only about11% of patients expected to survive five years after diagnosis, according to the American Cancer Society.

Desperate to find a cure, Wilkes began looking into new treatments when she came across a 2016 case study in a prestigious research journal, also published in theNEJM, that seemed promising.

The research was undertaken by a team of more than a dozens experts, including from the National Institutes of Health following a treatment that had already helped one 50-year-old woman with colon cancer become disease-free.

Wilkes discovered that her cancer had the same KRAS G12D mutation that was investigated in the study and didnt hesitate to contact the studys lead doctor, Eric Tran, now at the Providence Cancer Institute in Portland, Oregon.

When I talked to my hometown oncologist and asked him what to do, he only had one answer, and that was chemotherapy. And I said, Thats not my answer, Wilkes told NBC News in a report published Wednesday.

After discussing with the doctors, Wilkes was also offered the highlighted gene-editing treatment, which modifies her DNA so that it will produce immune cells that recognize and attack tumor cells. Only about 4% of pancreatic cancer patients have the mutation that responds to this treatment, though the same mutation has also been found in other cancers.

Within one month of the experimental therapy, Wilkes tumors had shrunk in half. After six months, the tumors had been reduced by 72%. And while shes not yet cancer-free, her cancer has not grown since she began treatment.

I thought, That is the trial I want. I knew that that was the trial that was going to save me, save my life. I just had that feeling, Wilkes said.

The Providence Cancer Institutes Dr. Rom Leidner, co-author of the new report on Wilkes cancer treatment, called it a one-and-done measure, in NBC News report, that modified her cancer-fighting immune cells to grow and multiply over time.

Wilkes response has been encouraging, but more research is needed. Another patient with pancreatic cancer who received the same treatment at the Providence Cancer Institute did not survive.

It was an encouraging result, but its certainly far from a cure, Dr. Eric Rubin, the New England Journal of Medicines editor-in-chief, said in a statement to NBC News.

Doctors are now recruiting patients for aPhase 1 clinical trialto continue the research.

See original here:
Deadly cancer quickly shrinks by 50% with 'one-and-done' therapy: study - New York Post

Recommendation and review posted by Bethany Smith

Small Study on Rectal Cancer Results in Remission in Every Patient – The New York Times

June 9th, 2022

It was a small trial, just 18 rectal cancer patients, every one of whom took the same drug.

But the results were astonishing. The cancer vanished in every single patient, undetectable by physical exam, endoscopy, PET scans or M.R.I. scans.

Dr. Luis A. Diaz Jr. of Memorial Sloan Kettering Cancer Center, an author of a paper published Sunday in the New England Journal of Medicine describing the results, which were sponsored by the drug company GlaxoSmithKline, said he knew of no other study in which a treatment completely obliterated a cancer in every patient.

I believe this is the first time this has happened in the history of cancer, Dr. Diaz said.

Dr. Alan P. Venook, a colorectal cancer specialist at the University of California, San Francisco, who was not involved with the study, said he also thought this was a first.

A complete remission in every single patient is unheard-of, he said.

These rectal cancer patients had faced grueling treatments chemotherapy, radiation and, most likely, life-altering surgery that could result in bowel, urinary and sexual dysfunction. Some would need colostomy bags.

They entered the study thinking that, when it was over, they would have to undergo those procedures because no one really expected their tumors to disappear.

But they got a surprise: No further treatment was necessary.

There were a lot of happy tears, said Dr. Andrea Cercek, an oncologist at Memorial Sloan Kettering Cancer Center and a co-author of the paper, which was presented Sunday at the annual meeting of the American Society of Clinical Oncology.

Another surprise, Dr. Venook added, was that none of the patients had clinically significant complications.

On average, one in five patients have some sort of adverse reaction to drugs like the one the patients took, dostarlimab, known as checkpoint inhibitors. The medication was given every three weeks for six months and cost about $11,000 per dose. It unmasks cancer cells, allowing the immune system to identify and destroy them.

While most adverse reactions are easily managed, as many as 3 percent to 5 percent of patients who take checkpoint inhibitors have more severe complications that, in some cases, result in muscle weakness and difficulty swallowing and chewing.

The absence of significant side effects, Dr. Venook said, means either they did not treat enough patients or, somehow, these cancers are just plain different.

In an editorial accompanying the paper, Dr. Hanna K. Sanoff of the University of North Carolinas Lineberger Comprehensive Cancer Center, who was not involved in the study, called it small but compelling. She added, though, that it is not clear if the patients are cured.

Very little is known about the duration of time needed to find out whether a clinical complete response to dostarlimab equates to cure, Dr. Sanoff said in the editorial.

Dr. Kimmie Ng, a colorectal cancer expert at Harvard Medical School, said that while the results were remarkable and unprecedented, they would need to be replicated.

The inspiration for the rectal cancer study came from a clinical trial Dr. Diaz led in 2017 that Merck, the drugmaker, funded. It involved 86 people with metastatic cancer that originated in various parts of their bodies. But the cancers all shared a gene mutation that prevented cells from repairing damage to DNA. These mutations occur in 4 percent of all cancer patients.

Patients in that trial took a Merck checkpoint inhibitor, pembrolizumab, for up to two years. Tumors shrank or stabilized in about one-third to one-half of the patients, and they lived longer. Tumors vanished in 10 percent of the trials participants.

That led Dr. Cercek and Dr. Diaz to ask: What would happen if the drug were used much earlier in the course of disease, before the cancer had a chance to spread?

They settled on a study of patients with locally advanced rectal cancer tumors that had spread in the rectum and sometimes to the lymph nodes but not to other organs. Dr. Cercek had noticed that chemotherapy was not helping a portion of patients who had the same mutations that affected the patients in the 2017 trial. Instead of shrinking during treatment, their rectal tumors grew.

Perhaps, Dr. Cercek and Dr. Diaz reasoned, immunotherapy with a checkpoint inhibitor would allow such patients to avoid chemotherapy, radiation and surgery.

Progress in the field. In recent years, advancementsin researchhave changed theway cancer is treated. Here are some recent updates:

The effect of weight loss. A new study found that people who lost significant amounts of weight through bariatric surgery had a 32 percent lower risk of developing cancerand a 48 percent lower risk of dying from cancer, compared with people who did not have the surgery. According to the study, the more weight people lost, the more their cancer risk fell.

Rectal cancer. A small trial that saw 18 rectal cancer patients taking the same drug, dostarlimab, appears to have produced an astonishing result: The cancer vanished in every single participant, undetectable by physical exam, endoscopy, PET scans or M.R.I. scans. Experts believe it to be the first time in history that a study has led to complete remission in every single cancer patient.

Pancreatic cancer. Researchers managed to tame advanced pancreatic cancer in a womanby genetically reprogramming her T cells, a type of white blood cell of the immune system, so they can recognize and kill cancer cells. Another patient who received the same treatment did not survive.

Chemotherapy. A quietrevolution isunderway in the field of cancer treatment: A growing number of patients, especially those with breast and lung cancers, are being spared the dreaded treatmentin favor of other options.

Leukemia. After receiving a new treatment, called CAR T cell therapy, more than a decade ago, two patients with chronic lymphocytic leukemia saw the blood cancer vanish. Their cases offer hope for those with the disease, and create some new mysteries.

Dr. Diaz began asking companies that made checkpoint inhibitors if they would sponsor a small trial. They turned him down, saying the trial was too risky. He and Dr. Cercek wanted to give the drug to patients who could be cured with standard treatments. What the researchers were proposing might end up allowing the cancers to grow beyond the point where they could be cured.

It is very hard to alter the standard of care, Dr. Diaz said. The whole standard-of-care machinery wants to do the surgery.

Finally, a small biotechnology firm, Tesaro, agreed to sponsor the study. Tesaro was bought by GlaxoSmithKline, and Dr. Diaz said he had to remind the larger company that they were doing the study company executives had all but forgotten about the small trial.

Their first patient was Sascha Roth, then 38. She first noticed some rectal bleeding in 2019 but otherwise felt fine she is a runner and helps manage a family furniture store in Bethesda, Md.

During a sigmoidoscopy, she recalled, her gastroenterologist said, Oh no. I was not expecting this!

The next day, the doctor called Ms. Roth. He had had the tumor biopsied. Its definitely cancer, he told her.

I completely melted down, she said.

Soon, she was scheduled to start chemotherapy at Georgetown University, but a friend had insisted she first see Dr. Philip Paty at Memorial Sloan Kettering. Dr. Paty told her he was almost certain her cancer included the mutation that made it unlikely to respond well to chemotherapy. It turned out, though, that Ms. Roth was eligible to enter the clinical trial. If she had started chemotherapy, she would not have been.

Not expecting a complete response to dostarlimab, Ms. Roth had planned to move to New York for radiation, chemotherapy and possibly surgery after the trial ended. To preserve her fertility after the expected radiation treatment, she had her ovaries removed and put back under her ribs.

After the trial, Dr. Cercek gave her the news.

We looked at your scans, she said. There is absolutely no cancer. She did not need any further treatment.

I told my family, Ms. Roth said. They didnt believe me.

But two years later, she still does not have a trace of cancer.

See the rest here:
Small Study on Rectal Cancer Results in Remission in Every Patient - The New York Times

Recommendation and review posted by Bethany Smith

Gene Therapy Market Share 2022 | Product Types and Application, Growth, Share, Top Key Players with Sales, Price, Business Overview – Digital Journal

June 9th, 2022

Astute Analytica publishes a research report on the global gene therapy market. The analysis report contains in-depth data about demand, growth, opportunities, challenges, and restraints. In addition, it provides a thorough examination of the structure and possibility of global and regional industries.

The globalgene therapy marketstudy includes information from key firms on R&D, new product launches, and product responses from global markets. The analysis includes a graphical presentation and a diagrammatic examination of the global gene therapy market by region.

The global gene therapy market size was US$ $$$ billion in 2020 and is forecast to reach US$ $$$ billion by 2027, growing at a compound annual growth rate (CAGR) of 24% during the forecast period from 2021 to 2027.

Request To Download Sample of This Strategic Report:https://www.astuteanalytica.com/request-sample/gene-therapy-market

People and economies globally rely substantially on the healthcare business. It is one of the fastest-growing industries. There is a correlation between income levels and healthcare spending in different nations, with healthcare spending accounting for more than 10% of most industrialized countries GDP.

The Centers for Medicare and Medicaid Services data calculates that the U.S. national healthcare expenditure reached US$ 4.1 trillion in 2020 and is forecast to surpass US$ 6.2 trillion by 2028. According to the Commonwealth Fund, the U.S. spent nearly 17% of gross domestic product (GDP) on healthcare in 2018. Switzerland was the second-highest-ranking country, spending 12.2%. In addition, New Zealand and Australia dedicate only 9.3%.

Regional Analysis:

According to the United States, Bureau of Labor Statistics, healthcare employment is likely to grow 16% from 2020 to 2030, much faster than the average for all occupations, with about 2.6 million new jobs. This projected increase is primarily due to an aging population, which indicates a higher demand for healthcare services. In May 2021, the median annual wage for healthcare practitioners and technical sectors (such as registered nurses, physicians and surgeons, and dental hygienists) was US$ 75,040, which was higher than the economys median annual wage of US$ 45,760.

Request To Download Sample of This Strategic Report:https://www.astuteanalytica.com/request-sample/gene-therapy-market

The European legislature and decision-makers should be aware that EU health systems are facing challenges arising from an aging population, citizens rising expectations, migration, and mobility of patients and health care professionals. Statista data shows the number of individuals employed in Europes hospitals in 2019. In 2019, there were more than 1.5 million people employed in hospitals in the UK, the largest number in Europe.

Impact Analysis of COVID-19:

Global COVID-19 cases have climbed above 516 million as of May 2022, and the death toll has exceeded 6.25 million. COVID-19 has disproportionately impacted specific racial and ethnic minority groups, as well as underserved and marginalized communities, highlighting the persistent challenges of health equity and health outcomes.

COVID-19 is causing a great deal of emotional, physical, and professional stress among health care personnel. The changing attitudes and behaviors of consumers, the integration of life sciences and health care, fast-growing digital health technology, new talent, and care delivery models, and clinical innovation advanced by COVID-19.

Request Full Report:https://www.astuteanalytica.com/request-sample/gene-therapy-market

As sector players and the customers, they serve to adapt to a new world of remote working, virtual doctor visits, and a supply chain plagued by shortages of medical goods, employees, and services, the sector is reforming to become more customer-centric.

About Astute Analytica:

Astute Analytica is a global analytics and advisory company that has built a solid reputation in a short period, thanks to the tangible outcomes we have delivered to our clients. We pride ourselves in generating unparalleled, in-depth, and uncannily accurate estimates and projections for our very demanding clients spread across different verticals. We have a long list of satisfied and repeat clients from a wide spectrum including technology, healthcare, chemicals, semiconductors, FMCG, and many more. These happy customers come to us from all across the globe.

They are able to make well-calibrated decisions and leverage highly lucrative opportunities while surmounting the fierce challenges all because we analyze for them the complex business environment, segment-wise existing and emerging possibilities, technology formations, growth estimates, and even the strategic choices available. In short, a complete package. All this is possible because we have a highly qualified, competent, and experienced team of professionals comprising business analysts, economists, consultants, and technology experts. In our list of priorities, you-our patron-come at the top. You can be sure of the best cost-effective, value-added package from us, should you decide to engage with us.

Get in touch with us:

Phone number: +18884296757

Email: [emailprotected]

Visit our website:https://www.astuteanalytica.com/

SOURCE Astute Analytica

Read the original:
Gene Therapy Market Share 2022 | Product Types and Application, Growth, Share, Top Key Players with Sales, Price, Business Overview - Digital Journal

Recommendation and review posted by Bethany Smith

New research finds nearly a third of melanomas found during skin checks may not be harmful, improving treatment options – ABC News

June 9th, 2022

Almost a third of melanomas picked up during routine skin checks may not be harmful, a study suggests.

Researchers followed tens of thousands of Queenslanders over seven years and found melanoma detections were significantly higher among the group who had their skin examined by a doctor before enrolment in the study.

QIMR Berghofer Medical Research Institute cancer scientist David Whiteman, who led the study, said the results suggested that up to 29 per cent of the melanomas detected during skin checks may never have come to light if that person had not been screened.

"It suggests that skin examinations and biopsies are picking up things that look and feel just like melanomas, but they don't always behave like them or cause harm," he said.

"Under the microscope, they look like a melanoma, on the skin they look like a melanoma. But for some reason, a proportion of them will just be there on your skin and never actually burrow deeper and never spread further."

Melanoma kills about 1,400 Australians every year, with more men dying than women.

Queensland has the highest rates of the skin cancer in the world.

Professor Whiteman said the research did not lessen the importance of Australians being sun safe and undergoing regular screening for skin cancers.

But it paved the way for some "exciting" research possibilities to improve the diagnosis and treatment of the disease.

"At this point in time, we can't tell which are the bad ones and which are the good ones," ProfessorWhiteman said.

"It might be an immune thing, it might be a genetic thing, it might be a molecular thing that as yet we can't detect that makes it less aggressive and more benign."

QIMR Berghofer genetic researchers are already investigating whether particular genes in melanoma cells influence the behaviour of the skin cancer, leading to the development of more serious disease.

"We want to be able to do a test to see whether or not certain melanomas themselves carry a mutation that makes their melanomas either more or less aggressive," ProfessorWhiteman said.

He said some people may also have inherited genes that made them less vulnerable to the effects of cancers.

"Those people might have a genetic susceptibility or a genetic strength, if you like, that increases or decreases the risk of a melanoma spreading in their body," he said.

Another possibility relates to the immune system differences.

"We do know that our immune systems do mount an immune response to cancers, particularly to melanomas," Professor Whiteman explained.

"Because melanomas are often highly mutated tumours, they often express lots of weird proteins on their surface, and those proteins can provoke an immune response.

"We know that the immune system is really important in fighting melanomas but whether or not that explains why some melanomas just sit there on the skin and don't progress we don't yet know."

The big hope is that more research will lead to the identification of triggers that switch a melanoma from being benign into an aggressive tumour.

"That trigger might be something that can be targeted with a designed drug or a designed genetic therapy that might be able to switch a gene on or off," ProfessorWhiteman said.

He said further studies may also lead to better diagnostic tools.

"Patients diagnosed with melanoma have to live with the fact they have a potentially fatal cancer and endure ongoing check-ups and scans," he said.

"If we can find a way to distinguish the melanomas with a good prognosis from the very nasty melanomas, we might be able to offer patients better information about their condition and more appropriate treatment options.

"It would also help alleviate pressure on the healthcare system as melanoma treatment is very, very costly."

Professor Whiteman urged Queenslanders to continue to "slip, slop, slap" even in winter.

"Every time you get exposed to the sun, there is the potential that damage can happen," he said.

"We still advocate that you're better off never getting a melanoma in the first place.

"Primary prevention remains our strong message but early detection also is extremely important."

Cancer Council Australia recommends that people regularly examine their skin and consult their doctor if they notice any changes such as a new spot or changes in the size, shape or colour of an existing spot.

Posted6 Jun 20226 Jun 2022Mon 6 Jun 2022 at 4:15am, updated6 Jun 20226 Jun 2022Mon 6 Jun 2022 at 6:02am

Go here to see the original:
New research finds nearly a third of melanomas found during skin checks may not be harmful, improving treatment options - ABC News

Recommendation and review posted by Bethany Smith

PINNACLE FERTILITY PARTNERS WITH IGENOMIX AS THEIR EXCLUSIVE GENETICS LABORATORY AND GENETIC COUNSELING PROVIDER – PR Newswire

June 9th, 2022

TAMPA, Fla., June 7, 2022 /PRNewswire/ -- Pinnacle Fertility (Pinnacle), the fastest-growing network of physician-centered fertility practices representing more than seven clinics and 20 locations nationwide, has partnered with Igenomix as their exclusive preimplantation genetics testing (PGT) laboratory and provider for genetic counseling services. Continuing Pinnacle's commitment to collaborative medical leadership and patient-first care, this strategic partnership was the result of the Medical Council's collective determination and offers patients an increased opportunity to find success in their family-building journey.

"Our Medical Director Council extensively studied the science behind major genetic labs to determine which would provide us with the best possible data to make key decisions. Bringing Igenomix on as our exclusive genetics provider for Pinnacle Fertility clinics continues to ensure that we meet our single guiding principle which is to provide the best patient outcomes possible," shares Dr. Richard Marrs, Chief Medical Director for Pinnacle Fertility.

With more than 15 years of experience, Igenomix is the global leader in reproductive genetics and focuses on quality, safety, and science to help healthcare professionals and patients detect genetic abnormalities before treatment, avoid implantation failure, and ensure patients achieve a healthy pregnancy.

"Pinnacle Fertility continues to set the standard in fertility care by bringing leading technology, integration and innovation to its suite of family building services. Partnerships with companies like Igenomix, who are committed though-leaders like we are, benefit our patients and those seeking to grow their families with the help world-class reproductive genetic testing and counseling services," says Andrew Mintz, CEO at Pinnacle Fertility.

PGT is an elective treatment option that can be used to identify embryos at risk of having a specific genetic or chromosomal condition and is available for patients at all fertility clinics within the Pinnacle network. Igenomix offers the most comprehensive portfolio of infertility treatments for genetics and was the first organization to launch non-invasive PGT-A services. Patients who choose to use PGT as part of their treatment plan receive complementary pre- and post-test genetic counseling to help guide and educate them on their options and results.

"Bringing Igenomix onboard is an exciting opportunity for our patients to seamlessly have access to genetic testing and counseling services, such as PGT at our fertility clinics," shares Dr. Dr. Priya Maseelallfrom Reproductive Gynecology and Infertility "The genetic counselors are perfectly integrated into our programs and champion our patients' success like we do."

Patients electing to use PGT, undergo in vitro fertilization (IVF) to create embryos, and then cells are removed from each embryo for genetic testing. Embryos with normal results are selected to be transferred into the uterus in hopes of achieving a pregnancy and delivering a child without a genetic condition. By utilizing PGT, genetic diseases can be prevented. In addition, studies have shown that PGT can not only improve success rates but also provide optimism and peace of mind during pregnancy and after birth.

About Pinnacle Fertility

Pinnacle Fertility is the nation's fastest-growing physician-centric fertility care platform, supporting high-performing fertility clinics and comprehensive fertility service providers nationwide. Under a united mission of fulfilling dreams by building families, Pinnacle clinics offer innovative technology and processes, compassionate patient care, and comprehensive fertility treatment services, ensuring families receive a high-touch experience on their path to parenthood.

For more information about Pinnacle Fertility, visit pinnaclefertility.com

About Igenomix

Igenomix is a global leader in reproductive genetic testing with laboratories in 23 countries and assisting hundreds of thousands of patients per year worldwide. As part of Vitrolife Group, the company is recognized for its R&D expertise and quality of service. In the US, Igenomix has proven to be the best-in-class when comes to credibility, consistency on their results, automatization of their laboratories and the most important, patient care.

Learn more about Igenomix at Igenomix.com

Contact:Walt Conrad[emailprotected]

SOURCE Pinnacle Fertility

Read more:
PINNACLE FERTILITY PARTNERS WITH IGENOMIX AS THEIR EXCLUSIVE GENETICS LABORATORY AND GENETIC COUNSELING PROVIDER - PR Newswire

Recommendation and review posted by Bethany Smith